fluorouracil has been researched along with Carcinoma, Ductal, Breast in 245 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Carcinoma, Ductal, Breast: An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This randomized phase III trial compared pathologic complete response (pCR) rates of early breast cancer (EBC) following neoadjuvant epirubicin-docetaxel (ED)±capecitabine (C), and evaluated the addition of trastuzumab in HER2-positive tumors." | 9.19 | Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). ( Bartsch, R; Dubsky, P; Fesl, C; Fitzal, F; Gampenrieder, SP; Gnant, M; Greil, R; Hartmann, BL; Hubalek, M; Jakesz, R; Lang, A; Melbinger, E; Mlineritsch, B; Muss, C; Petzer, AL; Ressler, S; Rudas, M; Singer, CF; Steger, GG; Stoeger, H; Zielinski, CC, 2014) |
| "To determine rates of pathologic complete response (pCR) and near-complete response (npCR) in operable early-stage breast cancer using neoadjuvant capecitabine plus docetaxel, with or without trastuzumab, and investigate biomarkers of pathologic response." | 9.16 | TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. ( Avisar, E; Glück, S; McKenna, EF; Perou, CM; Ross, JS; Royce, M; Wu, L, 2012) |
| "Women with axillary node-positive or high-risk node-negative breast cancer were randomly assigned to receive either three cycles of docetaxel and capecitabine (TX) followed by three cycles of cyclophosphamide, epirubicin, and capecitabine (CEX; n = 753) or three cycles of docetaxel (T) followed by three cycles of cyclophosphamide, epirubicin, and fluorouracil (CEF; n = 747)." | 9.16 | Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. ( Ahlgren, J; Asola, R; Auvinen, P; Bono, P; Helle, L; Huovinen, R; Joensuu, H; Jukkola-Vuorinen, A; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Leinonen, M; Lindman, H; Nilsson, G; Nyandoto, P; Paija, O; Pajunen, M; Poikonen, P; Tanner, M; Villman, K, 2012) |
| "To evaluate the efficacy and safety of docetaxel plus thiotepa(TXT/TSPA) and docetaxel plus capecitabine(TXT/CAPE) in patients with metastatic breast cancer." | 9.15 | [Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer]. ( Che, L; DI, Lj; Jia, J; Jiang, Hf; Liang, X; Ren, J; Song, Gh; Wang, Xl; Yang, Hb; Yu, J; Zhang, J; Zhou, Xn; Zhu, Yl, 2011) |
| "The purpose of this study was to investigate the activity of capecitabine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer resistant to both anthracyclines and taxanes." | 9.14 | Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes. ( Fukushima, M; Ishida, T; Ishioka, C; Ishiwata, R; Kiba, T; Masuda, N; Matsuyama, K; Noguchi, S; Ohuchi, N; Takatsuka, Y; Takeda, M; Teramukai, S, 2009) |
| "After breast cancer surgery, women with lymph node-positive disease were randomly assigned to treatment with fluorouracil, epirubicin, and cyclophosphamide (FEC) or with FEC followed by weekly paclitaxel (FEC-P)." | 9.13 | Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. ( Adrover, E; Alba, E; Almenar, S; Alvarez, I; Alvarez, JV; Antón, A; Aranda, E; Baena, JM; Calvo, L; Crespo, C; de Alava, E; García Puche, JL; Gonzalez, S; González-Palacios, JF; Gracia Marco, JM; Guitián, MD; Lluch, A; López García-Asenjo, JA; López-Vega, JM; Martín, M; Mayordomo, JI; Mel, JR; Modolell, A; Munárriz, B; Palacios, J; Pelegrí, A; Plazaola, A; Ramos, M; Rodríguez, CA; Rodríguez-Lescure, A; Ruiz, A; Ruiz-Borrego, M; Sánchez-Rovira, P; Seguí, MA; Vera, F, 2008) |
| "The purpose was to compare disease-free survival (DFS) between epirubicin-based chemoendocrine therapy and tamoxifen alone in one to three node-positive (N1-3), estrogen-receptor-positive (ER+), postmenopausal early breast cancer (EBC) patients." | 9.12 | Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 ( Bonneterre, J; Campone, M; Fargeot, P; Kerbrat, P; Luporsi, E; Monnier, A; Montcuquet, P; Namer, M; Roché, H; Romestaing, P, 2006) |
| "The combination of docetaxel and capecitabine provides a well-tolerated and active chemotherapy regimen for metastatic breast cancer." | 9.12 | [Efficacy of docetaxel combined capecitabine on metastatic breast cancer]. ( Jiang, WQ; Shi, YX; Wang, XX; Yuan, ZY; Zhang, DS; Zhou, ZM, 2007) |
| "Phase II study evaluating efficacy and safety of combined oxaliplatin/fluorouracil (5-FU) in taxane-pretreated advanced and metastatic breast cancer (ABC) patients." | 9.10 | Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients. ( Chollet, P; Chouaki, N; Cottu, P; Culine, S; Dieras, V; Gamelin, E; Mackenzie, S; Marty, M; Misset, JL; Spielmann, M; Tubiana-Hulin, M; Vannetzel, JM; Zelek, L, 2002) |
| "A 66-year-old woman with metastatic mammary carcinoma, who was being treated with capecitabine, contracted a herpes zoster infection that was treated with the antiviral drug brivudin." | 8.86 | Interaction between capecitabine and brivudin in a patient with breast cancer. ( Baena-Cañada, JM; García-Olmedo, O; Jiménez-Bárcenas, R; Martínez, MJ; Muriel-Cueto, P, 2010) |
| "To study the outcomes of adjuvant goserelin combined with tamoxifen (GosTam) compared to chemotherapy followed by tamoxifen (ChemTam) in premenopausal patients with early stage, luminal A breast cancer." | 7.83 | Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype. ( Alramadhan, M; Bae, SY; Kim, SW; Lee, JE; Lee, SK; Nam, SJ; Paik, HJ; Park, S; Rayzah, M; Ryu, JM; Yu, J, 2016) |
| " Two weeks after, she received her first cycle of cyclophosphamide, methotrexate, and 5FU (CMF) as a part of her breast cancer treatment." | 7.81 | Saddle pulmonary embolus and bronchiolitis obliterans with organizing pneumonia develop simultaneously after first cyclophosphamide, methotrexate, 5FU chemotherapy for breast cancer. ( Al-Hameed, FM, 2015) |
| "Capecitabine is an oral fluoropyrimidine derivative which is frequently used alone or in combination regimens for the treatment of metastatic breast cancer." | 7.80 | Lack of prognostic value of mean corpuscular volume with capecitabine therapy in metastatic breast cancer. ( Berk, V; Bozkurt, O; Cetin, B; Duran, AO; Inanc, M; Kaplan, MA; Karaca, H; Ozaslan, E; Ozkan, M, 2014) |
| "The aim of this study was to compare two regimens of chemotherapy in patients with breast cancer, including FAC (doxorubicin, cyclophosphamide, and 5-fluorouracil) and TAC (docetaxel, doxorubicin and cyclophosphamide); and analyze the toxicity of these treatments and observe patient's health-related quality of life." | 7.77 | Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil). ( Ahmad Kia Daliri, A; Ahmadloo, N; Askarian, M; Bastani, P; Hatam, N, 2011) |
| " We present a case of an ongoing 19-week-long pregnancy which was diagnosed in a 39-year-old woman who was being treated with CEF (cyclophosphamide, epirubicin, 5-fluorouracil) chemotherapy for an infiltrating ductal carcinoma of the breast." | 7.77 | Specific congenital malformations after exposure to cyclophosphamide, epirubicin and 5-fluorouracil during the first trimester of pregnancy. ( Breugelmans, M; De Greve, J; Foulon, W; Keymolen, K; Laubach, M; Leyder, M, 2011) |
| "We report a 55-year-old female with liver metastases from breast cancer who responded to lapatinib and capecitabine combination therapy as third-line." | 7.77 | [A case of breast cancer liver metastases responding to lapatinib and capecitabine therapy]. ( Ishiba, T; Kuwayama, T; Nakagawa, T; Oda, G; Sato, T; Sugihara, K; Sugimoto, H, 2011) |
| " In December 2004, paclitaxel and trastuzumab combination therapy was tried, but she went into shock just during administration of paclitaxel, and this therapy was discontinued." | 7.76 | [A case of HER2 overexpressing advanced breast cancer with CTF therapy [cyclophosphamide, pirarubicin (THPADM), fluorouracil] showed long-term effectiveness after paclitaxel shock]. ( Fujii, S; Ikeda, M; Kurebayashi, J; Miyake, A; Nakashima, K; Nomura, T; Oota, Y; Seki, M; Shiiki, S; Shimo, T; Sonoo, H; Tanaka, K; Yamamoto, Y, 2010) |
| "This study evaluated whether doxorubicin and cyclophosphamide are superior to cyclophosphamide, methotrexate and 5-fluorouracil as adjuvant chemotherapy in breast cancer patients." | 7.75 | Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer. ( Bianchi, S; Biti, GP; Borghesi, S; Cataliotti, L; De Luca Cardillo, C; Greto, D; Livi, L; Mangoni, M; Paiar, F; Saieva, C; Scotti, V, 2009) |
| "We report a case of metastatic breast cancer with leptomeninges and multiple bone metastases that showed an excellent response to the combination of trastuzumab and capecitabine; therapeutic effect was evaluated by MRI at follow-up." | 7.75 | Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report. ( Aogi, K; Fujiuchi, N; Matsuura, K; Misumi, M; Okubo, K; Osaki, A; Saeki, T; Sano, H; Shigekawa, T; Takeuchi, H, 2009) |
| "We report a case of elderly metastatic breast cancer with a complete response to the treatment with XC (X: capecitabine and C: cyclophosphamide)." | 7.74 | [A case of elderly metastatic breast cancer with a complete response to treatment with capecitabine and cyclophosphamide]. ( Furukawa, K; Iida, S; Iwasaki, R; Naito, Z; Noguchi, T; Sugisaki, Y; Tajiri, T; Tsuchiya, S; Yanagihara, K; Yokoyama, T, 2007) |
| "The aim of this study was to evaluate the efficacy and safety of neoadjuvant chemotherapy with infusional 5-fluorouracil (5-FU), adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer (LABC)." | 7.73 | Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis. ( Chung, HC; Jeung, HC; Moon, YW; Rha, SY; Suh, CO; Yang, WI, 2005) |
| "Paclitaxel and capecitabine have demonstrated a synergic effect and significant antitumor activity in patients with advanced breast cancer." | 7.73 | Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL. ( Bilancia, D; Cognetti, F; Di Costanzo, F; Gasperoni, S; Landucci, E; Manzione, L; Mazzoni, F; Papaldo, P, 2006) |
| "Topical application of 5-fluorouracil (5-FU) is one of the most effective clinical strategies available to treat actinic keratosis (AK)." | 7.73 | Actinic keratosis and capecitabine therapy. ( Abraham, J; Higa, GM; Kovach, RF, 2005) |
| "A considerable proportion of estrogen receptor (ER)-positive breast cancer recurs despite tamoxifen treatment, which is a serious problem commonly encountered in clinical practice." | 7.73 | Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer. ( Bae, JY; Bae, YJ; Han, MR; Han, W; Hwang, KT; Hwang, SE; Kang, JJ; Kim, SW; Lee, JE; Lee, JH; Noh, DY; Shin, HJ, 2006) |
| "We conducted a concomitant administration of capecitabine (2,400 mg/day for 21 days followed by a 7-day interval) and trastuzumab (2 mg/kg weekly) to a 73-year-old female patient with impaired lower limb function diagnosed with bilateral breast cancer." | 7.73 | [Case report of advanced breast cancer responding to capecitabine and trastuzumab combination therapy]. ( Hiraoka, K; Imabun, S; Nakahara, M; Nakao, K; Tsujimoto, M; Yamagami, Y; Yoshidome, K, 2006) |
| " We report two cases of NM from breast carcinoma and a third with esophageal carcinoma, which responded to treatment with capecitabine, an oral prodrug for 5-flurouracil." | 7.72 | Response of neoplastic meningitis from solid tumors to oral capecitabine. ( Giglio, P; Groves, MD; Tremont-Lukats, IW, 2003) |
| "The purpose of this study is to determine the characteristic clinical features, radiologic findings, and precipitating and prognostic factors in the patients with breast cancer and with 5-Fluorouracil (5-FU)-induced leukoencephalopathy." | 7.71 | 5-fluorouracil-induced leukoencephalopathy in patients with breast cancer. ( Cho, KH; Choi, SM; Kim, BC; Kim, MK; Lee, SH; Yang, YS, 2001) |
| "We herein report the case of a patient with recurrent breast cancer who showed a remarkable improvement in her quality of life (QOL) as a result of a good response to medroxyprogesterone acetate (MPA)." | 7.70 | Multidrug-resistant recurrent breast cancer which responded to medroxyprogesterone acetate showing a remarkable improvement in the quality of life: report of a case and the role of team medical care. ( Higashi, Y; Iino, Y; Ishiguro, S; Kurihara, T; Morishita, Y; Suemasu, K; Tabei, T; Takeda, F, 1998) |
| "To evaluate safety and efficacy of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer." | 7.70 | [A clinical report of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer]. ( Dai, A; Feng, J; Zheng, X, 1998) |
| "Sixty breast cancer patients undergoing an FEC60 regimen were enrolled, 37 patients completed the study." | 6.78 | The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study. ( Campanella, G; Clemente, C; D'Attoma, B; Giotta, F; Linsalata, M; Orlando, A; Riezzo, G; Russo, F, 2013) |
| "Among breast cancer patients, nonresponse to initial neoadjuvant chemotherapy is associated with unfavorable outcome." | 6.73 | Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. ( Costa, SD; Eidtmann, H; Gerber, B; Hanusch, C; Hilfrich, J; Huober, J; Jackisch, C; Kaufmann, M; Kümmel, S; Loibl, S; Mehta, K; Vogel, P; von Minckwitz, G, 2008) |
| "Capecitabine was started after the occurrence of new multiple lesions; complete regression was reached, which has now lasted over three years with continued capecitabine treatment." | 5.36 | [Long-term response of liver metastases of breast cancer to capecitabine--case report]. ( Macková, D, 2010) |
| "From January 2003 to March 2005, five breast cancer patients with brain metastases were referred for WBRT with concurrent capecitabine." | 5.35 | Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients. ( Campana, F; Castro Pena, P; Chargari, C; Cottu, PH; Diéras, V; Fourquet, A; Kirova, YM; Pena, PC; Pierga, J, 2009) |
| "She was diagnosed as inflammatory breast cancer clinically and invasive ductal carcinoma with lymphatic invasion pathologically." | 5.34 | [A case of inflammatory breast cancer achieving pathological complete response by primary systemic therapy with CEF (cyclophosphamide, epirubicin, 5-fluorouracil) followed by docetaxel]. ( Ando, M; Matsuyama, Y; Ooi, Y; Rai, Y; Sagara, Y; Takahama, T; Tamada, S; Tsuchimochi, S, 2007) |
| "Palmar-plantar erythrodysesthesia (PPE) is a distinctive and relatively frequent toxic reaction related to some chemotherapeutic agents." | 5.33 | Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction. ( Erkisi, M; Kara, IO; Sahin, B, 2006) |
| "For women with metastatic breast cancer, complete remission is uncommon, and stable disease is a reasonable goal of successful therapy." | 5.31 | Successful management of breast cancer with liver metastases with medroxyprogesterone acetate treatment. ( Hara, Y; Hikosaka, Y; Iwase, H; Kobayashi, S; Toyama, T; Yamashita, H, 2001) |
| " Women aged 65-79, operated for breast cancer, with average to high risk of recurrence, were allocated 1 : 1 to CMF (cyclophosphamide 600 mg/m², methotrexate 40 mg/m², fluorouracil 600 mg/m², days 1, 8) or docetaxel (35 mg/m(2) days 1, 8, 15) every 4 weeks, for four or six cycles according to hormone receptor status." | 5.20 | Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. ( Barni, S; Botti, G; Colantuoni, G; D'Aiuto, M; Daniele, B; Daniele, G; De Laurentiis, M; De Maio, E; de Matteis, A; De Placido, S; Di Maio, M; Di Rella, F; Forestieri, V; Gallo, C; Gori, S; Gravina, A; Iodice, G; Labonia, V; Landi, G; Lauria, R; Montanino, A; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Riccardi, F; Rossi, E; Signoriello, S; Tinessa, V, 2015) |
| "This randomized phase III trial compared pathologic complete response (pCR) rates of early breast cancer (EBC) following neoadjuvant epirubicin-docetaxel (ED)±capecitabine (C), and evaluated the addition of trastuzumab in HER2-positive tumors." | 5.19 | Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). ( Bartsch, R; Dubsky, P; Fesl, C; Fitzal, F; Gampenrieder, SP; Gnant, M; Greil, R; Hartmann, BL; Hubalek, M; Jakesz, R; Lang, A; Melbinger, E; Mlineritsch, B; Muss, C; Petzer, AL; Ressler, S; Rudas, M; Singer, CF; Steger, GG; Stoeger, H; Zielinski, CC, 2014) |
| "To determine rates of pathologic complete response (pCR) and near-complete response (npCR) in operable early-stage breast cancer using neoadjuvant capecitabine plus docetaxel, with or without trastuzumab, and investigate biomarkers of pathologic response." | 5.16 | TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. ( Avisar, E; Glück, S; McKenna, EF; Perou, CM; Ross, JS; Royce, M; Wu, L, 2012) |
| "Women with axillary node-positive or high-risk node-negative breast cancer were randomly assigned to receive either three cycles of docetaxel and capecitabine (TX) followed by three cycles of cyclophosphamide, epirubicin, and capecitabine (CEX; n = 753) or three cycles of docetaxel (T) followed by three cycles of cyclophosphamide, epirubicin, and fluorouracil (CEF; n = 747)." | 5.16 | Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. ( Ahlgren, J; Asola, R; Auvinen, P; Bono, P; Helle, L; Huovinen, R; Joensuu, H; Jukkola-Vuorinen, A; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Leinonen, M; Lindman, H; Nilsson, G; Nyandoto, P; Paija, O; Pajunen, M; Poikonen, P; Tanner, M; Villman, K, 2012) |
| "To evaluate the efficacy and safety of docetaxel plus thiotepa(TXT/TSPA) and docetaxel plus capecitabine(TXT/CAPE) in patients with metastatic breast cancer." | 5.15 | [Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer]. ( Che, L; DI, Lj; Jia, J; Jiang, Hf; Liang, X; Ren, J; Song, Gh; Wang, Xl; Yang, Hb; Yu, J; Zhang, J; Zhou, Xn; Zhu, Yl, 2011) |
| "The purpose of this study was to investigate the activity of capecitabine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer resistant to both anthracyclines and taxanes." | 5.14 | Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes. ( Fukushima, M; Ishida, T; Ishioka, C; Ishiwata, R; Kiba, T; Masuda, N; Matsuyama, K; Noguchi, S; Ohuchi, N; Takatsuka, Y; Takeda, M; Teramukai, S, 2009) |
| "After breast cancer surgery, women with lymph node-positive disease were randomly assigned to treatment with fluorouracil, epirubicin, and cyclophosphamide (FEC) or with FEC followed by weekly paclitaxel (FEC-P)." | 5.13 | Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. ( Adrover, E; Alba, E; Almenar, S; Alvarez, I; Alvarez, JV; Antón, A; Aranda, E; Baena, JM; Calvo, L; Crespo, C; de Alava, E; García Puche, JL; Gonzalez, S; González-Palacios, JF; Gracia Marco, JM; Guitián, MD; Lluch, A; López García-Asenjo, JA; López-Vega, JM; Martín, M; Mayordomo, JI; Mel, JR; Modolell, A; Munárriz, B; Palacios, J; Pelegrí, A; Plazaola, A; Ramos, M; Rodríguez, CA; Rodríguez-Lescure, A; Ruiz, A; Ruiz-Borrego, M; Sánchez-Rovira, P; Seguí, MA; Vera, F, 2008) |
| "The purpose was to compare disease-free survival (DFS) between epirubicin-based chemoendocrine therapy and tamoxifen alone in one to three node-positive (N1-3), estrogen-receptor-positive (ER+), postmenopausal early breast cancer (EBC) patients." | 5.12 | Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 ( Bonneterre, J; Campone, M; Fargeot, P; Kerbrat, P; Luporsi, E; Monnier, A; Montcuquet, P; Namer, M; Roché, H; Romestaing, P, 2006) |
| "The combination of docetaxel and capecitabine provides a well-tolerated and active chemotherapy regimen for metastatic breast cancer." | 5.12 | [Efficacy of docetaxel combined capecitabine on metastatic breast cancer]. ( Jiang, WQ; Shi, YX; Wang, XX; Yuan, ZY; Zhang, DS; Zhou, ZM, 2007) |
| "To evaluate tolerance and toxicity of high-dose epirubicin regimen CEF-100 as adjuvant therapy for breast cancer." | 5.12 | [Comparison of tolerance and toxicity of CEF-100 regimen versus CEF-60 regimen as adjuvant therapy for breast cancer]. ( Hao, XM; Hui, R; Zhang, J; Zhang, M, 2007) |
| "Within 7 years 263 women with stage II breast cancer were randomised either to receive 1 cycle of doxorubicin, vinblastine, cyclophosphamide, methotrexate and 5- fluorouracil (AV-CMF) or to receive 6 cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)." | 5.10 | Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients. ( Fridrik, M; Gnant, M; Haider, K; Hausmaninger, H; Jakesz, R; Kolb, R; Kubista, E; Mlineritsch, B; Ploner, F; Samonigg, H; Seifert, M; Steger, G; Steindorfer, P; Stierer, M; Tschurtschenthaler, G, 2003) |
| "Phase II study evaluating efficacy and safety of combined oxaliplatin/fluorouracil (5-FU) in taxane-pretreated advanced and metastatic breast cancer (ABC) patients." | 5.10 | Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients. ( Chollet, P; Chouaki, N; Cottu, P; Culine, S; Dieras, V; Gamelin, E; Mackenzie, S; Marty, M; Misset, JL; Spielmann, M; Tubiana-Hulin, M; Vannetzel, JM; Zelek, L, 2002) |
| "To evaluate ambulatory cancer chemotherapy, the clinical response, toxicities and survival time were analysed among 12 outpatients with recurrent breast cancer who were treated by sequential methotrexate (MTX)/5-FU therapy for the past 2 years." | 5.07 | [Clinical study of ambulatory cancer chemotherapy for recurrent breast cancer]. ( Kunii, Y; Nitta, A; Ota, K; Takahashi, N, 1994) |
| "From April 1990 to April 1992, a comparative study was carried out in 46 patients with advanced breast cancer treated by CMxMF (Cyclophosphamide, mitoxantrone, methotrexate, 5-fluorouracil) and CAMF regimens (Cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil)." | 5.07 | [Comparison of the therapeutic effect of CMxMF and CAMF regimens in the management of advanced breast cancer patients]. ( Chen, JA, 1993) |
| "A 66-year-old woman with metastatic mammary carcinoma, who was being treated with capecitabine, contracted a herpes zoster infection that was treated with the antiviral drug brivudin." | 4.86 | Interaction between capecitabine and brivudin in a patient with breast cancer. ( Baena-Cañada, JM; García-Olmedo, O; Jiménez-Bárcenas, R; Martínez, MJ; Muriel-Cueto, P, 2010) |
| "A 45-year-old woman with breast cancer who developed serpentine supravenous hyperpigmentation after intravenous 5-fluorouracil is described." | 4.86 | Antineoplastic agent-associated serpentine supravenous hyperpigmentation: superficial venous system hyperpigmentation following intravenous chemotherapy. ( Cohen, PR; Geddes, ER, 2010) |
| "To study the outcomes of adjuvant goserelin combined with tamoxifen (GosTam) compared to chemotherapy followed by tamoxifen (ChemTam) in premenopausal patients with early stage, luminal A breast cancer." | 3.83 | Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype. ( Alramadhan, M; Bae, SY; Kim, SW; Lee, JE; Lee, SK; Nam, SJ; Paik, HJ; Park, S; Rayzah, M; Ryu, JM; Yu, J, 2016) |
| " Two weeks after, she received her first cycle of cyclophosphamide, methotrexate, and 5FU (CMF) as a part of her breast cancer treatment." | 3.81 | Saddle pulmonary embolus and bronchiolitis obliterans with organizing pneumonia develop simultaneously after first cyclophosphamide, methotrexate, 5FU chemotherapy for breast cancer. ( Al-Hameed, FM, 2015) |
| "Capecitabine is an oral fluoropyrimidine derivative which is frequently used alone or in combination regimens for the treatment of metastatic breast cancer." | 3.80 | Lack of prognostic value of mean corpuscular volume with capecitabine therapy in metastatic breast cancer. ( Berk, V; Bozkurt, O; Cetin, B; Duran, AO; Inanc, M; Kaplan, MA; Karaca, H; Ozaslan, E; Ozkan, M, 2014) |
| "The association of motilin, ghrelin, leptin, gastrin, pepsinogen (PG) I and II with cancer chemotherapy-associated dyspepsia syndrome (CADS) was investigated in 35 patients with breast cancer receiving first cycle of 5-fluorouracil, cyclophosphamide, epirubicin (FEC60) chemotherapy." | 3.79 | Gut peptide profile and chemotherapy-associated dyspepsia syndrome in patients with breast cancer undergoing FEC60 chemotherapy. ( Campanella, G; Clemente, C; D'Attoma, B; Giotta, F; Linsalata, M; Orlando, A; Riezzo, G; Russo, F, 2013) |
| "To evaluate the effect of anthracycline pirarubicin-based regimen in association with different ways of fluorouracil (5-Fu) as neoadjuvant and adjuvant chemotherapy for primary breast cancer." | 3.78 | [Efficacy analysis of THP-containing regimens as neoadjuvant and adjuvant chemotherapy for primary breast cancer]. ( Fan, T; Fan, ZQ; Li, JF; Lin, BY; Ouyang, T; Wang, LZ; Wang, TF; Xie, YT, 2012) |
| "The aim of this study was to compare two regimens of chemotherapy in patients with breast cancer, including FAC (doxorubicin, cyclophosphamide, and 5-fluorouracil) and TAC (docetaxel, doxorubicin and cyclophosphamide); and analyze the toxicity of these treatments and observe patient's health-related quality of life." | 3.77 | Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil). ( Ahmad Kia Daliri, A; Ahmadloo, N; Askarian, M; Bastani, P; Hatam, N, 2011) |
| " We present a case of an ongoing 19-week-long pregnancy which was diagnosed in a 39-year-old woman who was being treated with CEF (cyclophosphamide, epirubicin, 5-fluorouracil) chemotherapy for an infiltrating ductal carcinoma of the breast." | 3.77 | Specific congenital malformations after exposure to cyclophosphamide, epirubicin and 5-fluorouracil during the first trimester of pregnancy. ( Breugelmans, M; De Greve, J; Foulon, W; Keymolen, K; Laubach, M; Leyder, M, 2011) |
| "Forty-three patients with 45 breast cancers were treated with neoadjuvant docetaxel-epirubicin with/without capecitabine chemotherapy." | 3.77 | Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer. ( Brodowicz, T; Csörgo, E; Kahán, Z; Kaizer, L; Lázár, G; Nikolényi, A; Ormándi, K; Sükösd, F; Thurzó, L; Uhercsák, G; Vörös, A, 2011) |
| "We report a 55-year-old female with liver metastases from breast cancer who responded to lapatinib and capecitabine combination therapy as third-line." | 3.77 | [A case of breast cancer liver metastases responding to lapatinib and capecitabine therapy]. ( Ishiba, T; Kuwayama, T; Nakagawa, T; Oda, G; Sato, T; Sugihara, K; Sugimoto, H, 2011) |
| " In December 2004, paclitaxel and trastuzumab combination therapy was tried, but she went into shock just during administration of paclitaxel, and this therapy was discontinued." | 3.76 | [A case of HER2 overexpressing advanced breast cancer with CTF therapy [cyclophosphamide, pirarubicin (THPADM), fluorouracil] showed long-term effectiveness after paclitaxel shock]. ( Fujii, S; Ikeda, M; Kurebayashi, J; Miyake, A; Nakashima, K; Nomura, T; Oota, Y; Seki, M; Shiiki, S; Shimo, T; Sonoo, H; Tanaka, K; Yamamoto, Y, 2010) |
| "This study evaluated whether doxorubicin and cyclophosphamide are superior to cyclophosphamide, methotrexate and 5-fluorouracil as adjuvant chemotherapy in breast cancer patients." | 3.75 | Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer. ( Bianchi, S; Biti, GP; Borghesi, S; Cataliotti, L; De Luca Cardillo, C; Greto, D; Livi, L; Mangoni, M; Paiar, F; Saieva, C; Scotti, V, 2009) |
| "We report a case of metastatic breast cancer with leptomeninges and multiple bone metastases that showed an excellent response to the combination of trastuzumab and capecitabine; therapeutic effect was evaluated by MRI at follow-up." | 3.75 | Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report. ( Aogi, K; Fujiuchi, N; Matsuura, K; Misumi, M; Okubo, K; Osaki, A; Saeki, T; Sano, H; Shigekawa, T; Takeuchi, H, 2009) |
| "We report a case of elderly metastatic breast cancer with a complete response to the treatment with XC (X: capecitabine and C: cyclophosphamide)." | 3.74 | [A case of elderly metastatic breast cancer with a complete response to treatment with capecitabine and cyclophosphamide]. ( Furukawa, K; Iida, S; Iwasaki, R; Naito, Z; Noguchi, T; Sugisaki, Y; Tajiri, T; Tsuchiya, S; Yanagihara, K; Yokoyama, T, 2007) |
| "We report the case of a 38-year-old man with metastatic ductal eccrine adenocarcinoma (DEA) of the left breast responding to 5-flourouracil, epirubicin and cyclophosphamide (FEC) chemotherapy." | 3.74 | Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast. ( Brock, CS; Eccles, S; Francis, N; Lim, A; McLean, SR; Nathan, M; Palmieri, C; Shousha, S, 2007) |
| "The aim of this study was to evaluate the efficacy and safety of neoadjuvant chemotherapy with infusional 5-fluorouracil (5-FU), adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer (LABC)." | 3.73 | Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis. ( Chung, HC; Jeung, HC; Moon, YW; Rha, SY; Suh, CO; Yang, WI, 2005) |
| "Paclitaxel and capecitabine have demonstrated a synergic effect and significant antitumor activity in patients with advanced breast cancer." | 3.73 | Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL. ( Bilancia, D; Cognetti, F; Di Costanzo, F; Gasperoni, S; Landucci, E; Manzione, L; Mazzoni, F; Papaldo, P, 2006) |
| "Topical application of 5-fluorouracil (5-FU) is one of the most effective clinical strategies available to treat actinic keratosis (AK)." | 3.73 | Actinic keratosis and capecitabine therapy. ( Abraham, J; Higa, GM; Kovach, RF, 2005) |
| "A considerable proportion of estrogen receptor (ER)-positive breast cancer recurs despite tamoxifen treatment, which is a serious problem commonly encountered in clinical practice." | 3.73 | Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer. ( Bae, JY; Bae, YJ; Han, MR; Han, W; Hwang, KT; Hwang, SE; Kang, JJ; Kim, SW; Lee, JE; Lee, JH; Noh, DY; Shin, HJ, 2006) |
| "We conducted a concomitant administration of capecitabine (2,400 mg/day for 21 days followed by a 7-day interval) and trastuzumab (2 mg/kg weekly) to a 73-year-old female patient with impaired lower limb function diagnosed with bilateral breast cancer." | 3.73 | [Case report of advanced breast cancer responding to capecitabine and trastuzumab combination therapy]. ( Hiraoka, K; Imabun, S; Nakahara, M; Nakao, K; Tsujimoto, M; Yamagami, Y; Yoshidome, K, 2006) |
| "We report a breast cancer patient who developed acute myeloid leukemia (AML) one year following her adjuvant chemotherapy consisting of cyclophosphamide, adriamycin and 5-fluorouracil." | 3.73 | t(8;16) AML developed subsequent to breast cancer therapy. ( Akçali, Z; Boğa, S; DemIrhan, B; Karakuş, S; Sahin, FI; Yilmaz, Z, 2006) |
| " We report two cases of NM from breast carcinoma and a third with esophageal carcinoma, which responded to treatment with capecitabine, an oral prodrug for 5-flurouracil." | 3.72 | Response of neoplastic meningitis from solid tumors to oral capecitabine. ( Giglio, P; Groves, MD; Tremont-Lukats, IW, 2003) |
| "The frequencies of chromosomal aberrations (CAs) and sister chromatid exchanges (SCEs) were determined in peripheral blood lymphocyte cultures from women with breast cancer treated by chemotherapy (CT) with FEC (5-fluorouracil, epirubicin, and cyclophosphamide) or CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) cocktail in six CT cycles." | 3.71 | Study of chromosome damage in patients with breast cancer treated by two antineoplastic treatments. ( Carrara, HH; Silva, LM; Takahashi, CS, 2002) |
| "The purpose of this study is to determine the characteristic clinical features, radiologic findings, and precipitating and prognostic factors in the patients with breast cancer and with 5-Fluorouracil (5-FU)-induced leukoencephalopathy." | 3.71 | 5-fluorouracil-induced leukoencephalopathy in patients with breast cancer. ( Cho, KH; Choi, SM; Kim, BC; Kim, MK; Lee, SH; Yang, YS, 2001) |
| "Carmofur (1-hexylcarbamyl-5-fluorouracil), a derivative of 5-fluorouracil (5-FU), has been widely used in Japan as a postoperative adjuvant chemotherapy agent for colorectal and breast cancer." | 3.71 | Diffusion-weighted MR imaging of Carmofur-induced leukoencephalopathy. ( Fujikawa, A; Hachiya, J; Katase, S; Kurosaki, Y; Tsuchiya, K, 2001) |
| "Gemcitabine and capecitabine are nucleoside analogues used in chemotherapy strategies for the treatment of breast cancer." | 3.71 | Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. ( Baldwin, SA; Cass, CE; Clarke, ML; Coupland, RW; Dabbagh, L; Jennings, LL; Koski, SL; Mackey, JR; Santos, CL; Vsianska, M; Young, JD, 2002) |
| " We examined TP expression using immunohistochemistry (654-1 Mab) in 182 invasive breast carcinomas (67 N0 and 115 N1/2; median follow-up 78 months [range, 3-177]; 51 patients treated with adjuvant systemic cyclophosphamide, methotrexate and 5-fluorouracil [CMF] chemotherapy and 82 with tamoxifen)." | 3.71 | Prognostic value of thymidine phosphorylase expression in breast carcinoma. ( Barbareschi, M; Caffo, O; Dalla Palma, P; Galligioni, E; Kakudo, K; Mauri, F; Mori, I; Muscarà, M; Nakamura, M; Nakamura, Y; Sakurai, T; Yang, Q; Yoshimura, G, 2002) |
| "We herein report the case of a patient with recurrent breast cancer who showed a remarkable improvement in her quality of life (QOL) as a result of a good response to medroxyprogesterone acetate (MPA)." | 3.70 | Multidrug-resistant recurrent breast cancer which responded to medroxyprogesterone acetate showing a remarkable improvement in the quality of life: report of a case and the role of team medical care. ( Higashi, Y; Iino, Y; Ishiguro, S; Kurihara, T; Morishita, Y; Suemasu, K; Tabei, T; Takeda, F, 1998) |
| "To evaluate safety and efficacy of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer." | 3.70 | [A clinical report of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer]. ( Dai, A; Feng, J; Zheng, X, 1998) |
| "Two hundred and sixteen T2 breast cancer patients were treated consecutively with surgery followed by 5'DFUR (600 mg/body/day) + tamoxifen (20 mg/body/day) for 2 years." | 3.70 | Intratumoral pyrimidine nucleoside phosphorylase (PyNPase) activity predicts a selective effect of adjuvant 5'-deoxy-5-fluorouridine (5'DFUR) on breast cancer. ( Akasaka, Y; Hata, Y; Nakanishi, Y; Ogita, M; Sasaki, F; Sawada, Y; Takahashi, H; Uchino, J; Yoshimoto, M, 2000) |
| "Between 1975 and 1986, 326 patients with stage II breast cancer were treated with an adjuvant combination of doxorubicin, vincristine, cyclophosphamide, and 5-fluorouracil (AVCF) following regional therapy (232 modified radical mastectomy, 94 lumpectomies, 304 irradiations)." | 3.69 | Adjuvant chemotherapy with doxorubicin-containing regimen for 326 stage II breast cancers: 15-year results. ( Achard, JL; Bélembaogo, E; Charrier, S; Chollet, P; Courtadon, M; Curé, H; Dauplat, J; de Latour, M; Ferrière, JP; Kwiatkowski, F, 1997) |
| "Given the proven prognostic value of circulating tumor cells (CTCs) in EBC, we compared the prevalence of CTCs after chemotherapy between both treatment arms for a preliminary efficacy assessment." | 2.84 | Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer. ( Alunni-Fabbroni, M; Andergassen, U; Camara, O; de Gregorio, N; Decker, T; Fasching, PA; Fehm, TN; Friedl, TWP; Heinrich, G; Jaeger, B; Janni, W; Mahner, S; Ober, A; Pantel, K; Rack, BK; Schneeweiss, A; Schochter, F; Schramm, A; Trapp, E, 2017) |
| "Overall accuracy of the residual cancer burden score determination was 0." | 2.80 | Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy. ( Albarracin, C; Downs-Kelly, E; Gould, R; Hatzis, C; Morkowski, J; Peintinger, F; Sinn, B; Symmans, WF, 2015) |
| "Adjuvant trastuzumab in combination with chemotherapy improves survival of women with HER2-positive early breast cancer." | 2.80 | Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). ( Boukovinas, I; Georgoulias, V; Kakolyris, S; Kentepozidis, N; Malamos, N; Mavroudis, D; Papakotoulas, P; Saloustros, E; Ziras, N, 2015) |
| "Their effect in early breast cancer is controversial." | 2.78 | German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. ( Barinoff, J; Bauerfeind, I; Belau, A; Clemens, M; Conrad, B; Diel, IJ; Elling, D; Forstbauer, H; Harbeck, N; Huober, J; Jackisch, C; Kreienberg, R; Loibl, S; Lück, HJ; Möbus, V; Müller, V; Nekljudova, V; Noeding, S; Schmidt, M; Schneeweiss, A; Thomssen, C; Untch, M; von Minckwitz, G, 2013) |
| "Sixty breast cancer patients undergoing an FEC60 regimen were enrolled, 37 patients completed the study." | 2.78 | The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study. ( Campanella, G; Clemente, C; D'Attoma, B; Giotta, F; Linsalata, M; Orlando, A; Riezzo, G; Russo, F, 2013) |
| " We have previously demonstrated that by means of a comprehensive dietary modification which aims at lowering insulin levels it is possible to reduce body weight and decrease the bioavailability of insulin, sex hormones and the growth factors linked to BC risk and prognosis." | 2.77 | Preventing weight gain during adjuvant chemotherapy for breast cancer: a dietary intervention study. ( Berrino, F; Bruno, E; Curtosi, P; Evangelista, A; Gargano, G; Morelli, D; Pasanisi, P; Raimondi, M; Villarini, A, 2012) |
| "MAI (≥ 10) was strongly associated with breast cancer-related death in lymph node (LN)-negative patients (hazard ratio (HR): 7." | 2.76 | Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients. ( Baak, JP; Gilje, B; Janssen, EA; Nordgård, O; Smaaland, R; Søiland, H; Tjensvoll, K, 2011) |
| "Among breast cancer patients, nonresponse to initial neoadjuvant chemotherapy is associated with unfavorable outcome." | 2.73 | Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. ( Costa, SD; Eidtmann, H; Gerber, B; Hanusch, C; Hilfrich, J; Huober, J; Jackisch, C; Kaufmann, M; Kümmel, S; Loibl, S; Mehta, K; Vogel, P; von Minckwitz, G, 2008) |
| "We studied how gastric cancer tissues and cells changed as a result of preoperative chemotherapy." | 2.68 | [Influence of preoperative on gastric cancer tissues and cells]. ( Chen, Z; Li, G; Liu, F, 1997) |
| "A 62-year-old woman being treated for chronic hepatitis C and high blood pressure was shown by computed tomography to have tumors in the lateral and medial segments of her liver, and in her right breast." | 2.48 | [Liver arterial infusion chemotherapy with adjuvant trastuzumab for the simultaneous treatment of liver and breast cancer-a case report]. ( Akashi, M; Fujii, T; Inoue, Y; Momosaki, S; Nakayama, Y; Nishida, R; Saitsu, H; Shirouzu, K; Takahashi, H; Takahashi, R; Takami, Y; Takayoshi, K; Uchino, K, 2012) |
| "Triple-negative breast cancer (TNBC) often grows rapidly and has poor outcomes, with a high recurrence rate and a short interval between recurrence and death." | 2.47 | Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy. ( Kajiura, Y; Yagata, H; Yamauchi, H, 2011) |
| "Male breast cancer is a rare disease and the incidence has increased over the past 25 years." | 2.44 | [Clinical research advancement on male breast cancer]. ( Guo, XT; Liu, WC; Xue, Y, 2007) |
| "Selected patients with inflammatory breast cancer have the potential for long-term survival." | 2.42 | Ten-year outcome after combined modality therapy for inflammatory breast cancer. ( Bertsch, H; Fox, K; Glick, J; Harris, EE; Schultz, D; Solin, LJ, 2003) |
| "Secondary spontaneous pneumothorax (SSP) is a rare complication of chemotherapy for pulmonary metastases and to the best of our knowledge, only 28 cases have been described, most of which occurred in patients with osteosarcoma or germ cell tumors." | 2.41 | Bilateral recurrent pneumothorax complicating chemotherapy for pulmonary metastatic breast ductal carcinoma: report of a case. ( Ansaloni, L; Bazzocchi, R; Bini, A; Grazia, M; Stella, F; Zompatori, M, 2000) |
| "We retrospectively examined breast cancer patients with luminal human epidermal growth factor receptor 2 (HER2)-negative tumours, as defined by immunohistochemistry, who received neo-adjuvant chemotherapy (NAC) and investigated the relationship between treatment effects and FOXA1 expression." | 1.42 | Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases. ( Arakawa, A; Harada-Shoji, N; Himuro, T; Hino, O; Horimoto, Y; Igari, F; Mamat, O; Saito, M; Sonoue, H; Tanabe, M; Tokuda, E; Yoshida, Y, 2015) |
| "Patients with primary HER2-positive breast cancer treated with trastuzumab-based NST were categorised according to adjuvant trastuzumab administration and pCR status." | 1.42 | Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy. ( Chavez-MacGregor, M; Gonzalez-Angulo, AM; Hortobagyi, GN; Hunt, KK; Lei, X; Mittendorf, EA; Parinyanitikul, N; Valero, V; Zhang, H, 2015) |
| "Primary breast cancer patients (stage II-III) preoperatively treated with sequential paclitaxel (12 cycles) and fluorouracil, epirubicin, and cyclophosphamide (4 cycles), followed by surgery were retrospectively enrolled, and 229 patients were eligible." | 1.42 | Prediction of pathological complete response to neoadjuvant chemotherapy by magnetic resonance imaging in breast cancer patients. ( Kagara, N; Kim, SJ; Maruyama, N; Michishita, S; Naoi, Y; Noguchi, S; Shimazu, K; Shimoda, M; Shimomura, A; Sota, Y, 2015) |
| "Tamoxifen use was associated with elevated estradiol levels 1 year post-chemotherapy." | 1.40 | Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer. ( Ng, CH; Rozita, AM; Taib, NA; Tiong, V; Yip, CH, 2014) |
| "Out of 322 patients with breast cancer registered in our institute, 80 patients received neoadjuvant chemotherapy." | 1.40 | The actual scenario of neoadjuvant chemotherapy of breast cancer in developing country: a report of 80 cases of breast cancer from a tertiary cancer center in India. ( Babu, S; Das, U; Govind Babu, K; Jacob, L; Lakshmaiah, KC; Lokanatha, D; Suresh, TM, 2014) |
| "The triple negative breast cancer (TNBC) was most sensitive to chemotherapy with 19% achieving clinical-complete-response (cCR) followed by HER2 enriched (2/22 (9%) cCR), luminal B (1/6 (7%) cCR) and luminal A (0/10 (0%) cCR)." | 1.39 | Association of immunohistochemically defined molecular subtypes with clinical response to presurgical chemotherapy in patients with advanced breast cancer. ( Khokher, S; Mahmood, S; Nagi, AH; Qureshi, MU, 2013) |
| "The role of aromatase inhibitors combined with gonadotropin-releasing hormone analog in metastatic male breast cancer patients remains unknown." | 1.39 | Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. ( Barba, M; Del Medico, P; Di Lauro, L; Giannarelli, D; Laudadio, L; Maugeri-Saccà, M; Pizzuti, L; Sergi, D; Tomao, S; Vici, P, 2013) |
| "In patients with HER2-overexpressed breast cancer, the positive rate of HER2ECD was significantly higher (24." | 1.39 | Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer. ( Date, M; Fujiwara-Honjo, N; Haba, R; Hashimoto, S; Houchi, H; Kontani, K; Kuroda, N; Kushida, Y; Murazawa, C; Norimura, S; Ohtani, M; Tanaka, H; Yamauchi, A; Yokomise, H, 2013) |
| "One hundred and forty-nine breast cancer patients eligible for neoadjuvant chemotherapy were included in the study between February 2004 and January 2009 at three centers." | 1.39 | Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy. ( Blot, E; Bonneterre, J; Desauw, C; Fournier, C; Hornez, L; Kramar, A; Peyrat, JP; Révillion, F, 2013) |
| "Locoregional treatment of inflammatory breast cancer (IBC) is crucial because local relapses may be highly symptomatic and are commonly associated with distant metastasis." | 1.38 | Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up. ( Arriagada, R; Bourgier, C; Dunant, A; Heymann, S; Marsiglia, H; Mathieu, MC; Pessoa, EL; Spielmann, M; Uzan, C, 2012) |
| "Patients with early breast cancer with highly proliferative (S-phase fraction >4%) operable tumors of >3 cm received 4 cycles of intensified neoadjuvant chemotherapy with high-dose cyclophosphamide (doxorubicin 70 mg/m d1, cyclophosphamide 700 mg/m d1/d8, and 5 FU 700 mg/m d1-d5) every 3 weeks." | 1.38 | Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer. ( Alran, S; Beuzeboc, P; Dettwiler, S; Diéras, V; Fréneaux, P; Laurence, V; Le Tourneau, C; Pierga, JY; Sigal-Zafrani, B; Vincent-Salomon, A, 2012) |
| "Adjacent ductal carcinoma in situ (DCIS) is found in approximately 45% of invasive ductal carcinomas (IDC) of the breast." | 1.38 | Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40). ( Clemens, MR; Darb-Esfahani, S; Denkert, C; Diebold, K; Dietrich, K; Eidtmann, H; Hanusch, C; Henschen, S; Hoffmann, G; Holms, F; Huober, J; Just, M; Loibl, S; Schrader, I; Solbach, C; Tesch, H; Tiemann, K; Untch, M; von Minckwitz, G, 2012) |
| "Data from 199 stage II-III breast cancer patients who failed to achieve pCR after NCT were used." | 1.38 | A prognostic model to predict outcome of patients failing to achieve pathological complete response after anthracycline-containing neoadjuvant chemotherapy for breast cancer. ( Chen, CM; Chen, S; Shao, ZM; Yang, WT; Yu, KD, 2012) |
| "Data from 224 stage II-III breast cancer patients with positive HR status before NCT who had residual disease in the breast after NCT were collected." | 1.38 | Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer. ( Chen, CM; Chen, S; Shao, ZM; Yu, KD; Zhou, RJ, 2012) |
| "Among the low and intermediate grade breast cancers, the FGFR1 negative tumors were resistant to chemoradiotherapy." | 1.38 | The fibroblast growth factor receptor 1 (FGFR1), a marker of response to chemoradiotherapy in breast cancer? ( Belin, L; Cohen-Jonathan-Moyal, E; Fourquet, A; Hall, J; Kirova, YM; Massabeau, C; Mégnin-Chanet, F; Richardson, M; Savignoni, A; Sigal-Zafrani, B, 2012) |
| "Patients with locally advanced breast cancer treated with neoadjuvant chemotherapy are at risk of cancer treatment-induced bone loss and consequently of increased skeletal morbidity." | 1.38 | Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy. ( Bleuse, JP; Chapelle, A; Jacot, W; Lamy, PJ; Pouderoux, S; Romieu, G; Thezenas, S, 2012) |
| "In early-stage breast cancer, radiotherapy delivered after conservative surgery leads to a reduction in the risk of local recurrences by approximately two thirds." | 1.38 | [A case of cutaneous mammary re-irradiation]. ( Bollet, MA; Fourchotte, V; Jacob, J; Kirova, YM; Pierga, JY, 2012) |
| "One hundred and fourteen cases of breast cancer with NA therapy were analyzed and clinical data were collected from March 2007 to December 2010." | 1.37 | [Primary systemic therapy in breast cancer patients (2007-2010)]. ( Farkas, R; Horváth, OP; Kálmán, E; Kovács, G; Kövér, E; Pavlovics, G; Szalai, G; Tizedes, G; Zapf, I, 2011) |
| "Sixty five patients with breast cancer underwent (99)Tc(m)-MIBI scintimammography before NCT, and static planar images were taken at 10 min and 180 min after scintimammography." | 1.37 | [Predictive value of (99)Tc(m)-MIBI scintimammography in evaluation of the efficacy of neoadjuvant chemotherapy in patients with operable breast cancer]. ( Cui, SD; Li, LF; Li, WL; Liu, H; Liu, ZZ; Lu, ZD; Yang, H; Zhang, HW, 2011) |
| "Little is known about its role in breast cancer progression." | 1.36 | Rho GDP dissociation inhibitor alpha expression correlates with the outcome of CMF treatment in invasive ductal breast cancer. ( Dittmer, A; Dittmer, J; Holzhausen, HJ; Kantelhardt, E; Ronneburg, H; Schunke, D; Span, PN; Sweep, FC, 2010) |
| "Sixty-eight female breast cancer patients were included." | 1.36 | Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy. ( Afsar, NA; Ahmad, HR; Ahmed, KZ; Cascorbi, I; Haenisch, S; Mateen, A; Ufer, M; Usman, A, 2010) |
| "Capecitabine was started after the occurrence of new multiple lesions; complete regression was reached, which has now lasted over three years with continued capecitabine treatment." | 1.36 | [Long-term response of liver metastases of breast cancer to capecitabine--case report]. ( Macková, D, 2010) |
| "Locally-advanced female breast cancer patients [AJCC Stages IIIA, IIIB, IIIC], seen in the breast clinic from July, 2006 to March 2007 were recruited into the study after informed consent." | 1.36 | Neoadjuvant chemotherapy for locally advanced premenopausal breast cancer in Nigerian women: early experience. ( Anyanwu, SN; Chukwuanukwu, TO; Ihekwoaba, E; Mbaeri, AT; Nwose, P, 2010) |
| "A patient with inflammatory breast carcinoma (IBC) diagnosed in the left breast responded to cisplatin and was treated with radical mastectomy and adjuvant therapy." | 1.35 | Bilateral inflammatory metachronic ERBB2 (HER2/neu)-positive breast carcinoma: prolonged survival with combined chemotherapy and trastuzumab. ( Amorós, A; Casinello, J; Heredia, M; Lázaro, A; López-Alfonso, A, 2008) |
| "From January 2003 to March 2005, five breast cancer patients with brain metastases were referred for WBRT with concurrent capecitabine." | 1.35 | Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients. ( Campana, F; Castro Pena, P; Chargari, C; Cottu, PH; Diéras, V; Fourquet, A; Kirova, YM; Pena, PC; Pierga, J, 2009) |
| "The effects of capecitabine on two breast carcinoma cell lines were evaluated by the status of both cell proliferation and apoptosis and mRNA levels of TP and DPD were also determined." | 1.35 | Expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in human breast carcinoma cells and tissues. ( Chow, LW; Hirakawa, H; Ishida, T; Loo, WT; Ohuchi, N; Ono, K; Sasano, H; Suzuki, T, 2009) |
| "From April 1998 to April 2004, 112 breast cancer patients were treated with neoadjuvant chemotherapy." | 1.35 | [Efficacy of neoadjuvant chemotherapy with FEC and TEC regimen on breast cancer]. ( Fu, JF; Hong, ZW; Wang, B, 2009) |
| "Forty-one female patients with advanced breast cancer before and after chemotherapy and 60 healthy females participated in the study." | 1.35 | DNA damage in peripheral blood lymphocytes in patients during combined chemotherapy for breast cancer. ( Benítez-Bribiesca, L; Bravo, JL; Del Castillo, ER; Gallegos-Hernández, F; Ostrosky-Wegman, P; Peñarroja-Flores, R; Sánchez-Suárez, P; Toledo-García, J, 2008) |
| "She was diagnosed as inflammatory breast cancer clinically and invasive ductal carcinoma with lymphatic invasion pathologically." | 1.34 | [A case of inflammatory breast cancer achieving pathological complete response by primary systemic therapy with CEF (cyclophosphamide, epirubicin, 5-fluorouracil) followed by docetaxel]. ( Ando, M; Matsuyama, Y; Ooi, Y; Rai, Y; Sagara, Y; Takahama, T; Tamada, S; Tsuchimochi, S, 2007) |
| "Female breast cancer is one of the major causes of death among women while male breast cancer is relatively uncommon and accounts for about 1% of all breast cancers in both sexes." | 1.34 | Male breast cancer with mandibular metastasis. A case report. ( Amaddeo, P; Barbaglio, A; Faldi, F; Fontana, S; Ghilardi, R; Pericotti, S, 2007) |
| "All cases of breast carcinoma diagnosed during the period from 1989 to 2001 were retrospectively reviewed." | 1.34 | [Diagnosis and prognosis study of breast carcinoma with micropapillary component]. ( Chen, L; Fan, Y; Fu, L; Guo, XJ; Lang, RG; Sun, YL, 2007) |
| "It seems that the quality of life for breast cancer patients was affected by the extent of the alopecia." | 1.33 | [A case of advanced breast cancer markedly responding to chemo-endocrine therapy with only slight alopecia]. ( Iwakuma, N; Nagamatsu, H; Ono, H; Shirouzu, K; Terazaki, Y, 2005) |
| "We analyzed TS and DPD expression in breast carcinomas to evaluate the clinicopathological significance of these enzymes in patients with invasive breast cancer receiving 5-FU-based chemotherapy." | 1.33 | Thymidylate synthase predicts for clinical outcome in invasive breast cancer. ( Sun, J; Yang, Q; Yu, Z; Zhang, Q; Zhen, J, 2005) |
| "Palmar-plantar erythrodysesthesia (PPE) is a distinctive and relatively frequent toxic reaction related to some chemotherapeutic agents." | 1.33 | Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction. ( Erkisi, M; Kara, IO; Sahin, B, 2006) |
| "The incidence of brain metastases from breast cancer seems to be increasing with the improvement of systemic control and survival prolongation." | 1.33 | [Clinical analysis of 67 patients with brain metastases from breast cancer]. ( Feng, FY; He, J; Wang, XY; Xing, PY; Zhang, P, 2005) |
| "Capecitabine is a new chemotherapeutic agent considered highly specific for sensitive tumour cells, which convert the drug to 5-fluorouracil." | 1.33 | Coronary artery spasm induced by capecitabine. ( Barone, C; Cassano, A; Crea, F; Lanza, GA; Pozzo, C; Sestito, A; Sgueglia, GA, 2006) |
| "S-1 could be a valuable agent for breast cancer treatments, since it showed clinical efficacy and mild toxicity, and can be given orally." | 1.33 | S-1 (TS-1) maintained complete response for approximately 10 years in a case of metastatic breast cancer. ( Aogi, K; Doihara, H; Nishimura, R; Ohsumi, S; Saeki, T; Taira, N; Takashima, S, 2006) |
| "The majority of deaths due to breast cancer occur in the context of complications secondary to metastatic disease." | 1.33 | A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapy. ( Carrato Mena, A; Guillén Ponce, C; Maciá Escalante, S; Martínez Banaclocha, N; Pons Sanz, V; Rodríguez Lescure, A, 2006) |
| "Simultaneous presentation of breast cancer and malignant phyllodes tumour is rare." | 1.33 | Infiltrating ductal carcinoma and synchronous malignant phyllodes tumour. Diagnostic and therapeutic approaches. ( Calpena, R; Cansado Martínez, P; Lacueva Gómez, FJ; Martínez Banaclocha, N; Merck, B; Pérez Ramos, M, 2006) |
| "Although studies have focused on modulating the bioavailability of 5-FU through inhibition of dihydropyrimidine dehydrogenase (DPD) to improve efficacy of the drug, activity of this enzyme in breast cancer has not been thoroughly examined." | 1.32 | Increased dihydropyrimidine dehydrogenase activity in breast cancer. ( Abe, Y; Anan, K; Iwashita, T; Mitsuyama, S; Nishihara, K; Ogawa, Y; Suehara, N; Tamae, K; Toyoshima, S, 2003) |
| "The treated breast carcinoma cells were tubulin-positive but the proliferating histiocytes were tubulin-negative." | 1.32 | Pseudoneoplastic proliferation of histiocytes with paclitaxel-induced ultrastructural changes in a mastectomy specimen. ( Garg, K; Lemos, LB; Papasozomenos, S; Qu, Z, 2004) |
| "From 59 breast cancer patients treated with neoadjuvant chemotherapy and 33 without neoadjuvant therapy (control), core biopsy samples before the chemotherapy or surgery and surgical specimens were obtained for assay of ER, PR, and HER-2 expression." | 1.32 | [Effects of neoadjuvant chemotherapy on estrogen and progesterone receptors and HER-2 in breast cancer]. ( Wang, J; Wang, YD; Wu, YL; Zhao, GR; Zhao, J, 2004) |
| "Cytogenetic abnormalities were not found in the stem cell harvests of these patients by metaphase analysis or by fluorescence in situ hybridization (FISH)." | 1.31 | Therapy-related myelodysplastic syndrome after autologous stem cell transplantation for breast cancer. ( de Castro, K; Griffin, M; Hesdorffer, C; Lin, N; Murty, VV; Nichols, G; Oratzi, A; Troxel, A; Vahdat, L; Wei, LX, 2002) |
| "The follow up didn't show a relapse of breast carcinoma after 5 years." | 1.31 | [Breast carcinoma in accessory gland: a case report]. ( Arcuri, MF; Corcione, L; Del Rio, P; Sivelli, R, 2002) |
| "We found that the hazard function of metastasis in time presented two peaks of incidence at 20 and 60 months, respectively." | 1.31 | Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy. ( Biganzoli, E; Bonoldi, E; Boracchi, P; Fanelli, M; Gasparini, G; Morabito, A, 2001) |
| "240 patients with unresectable breast cancer were treated with curative radio- and chemo- or hormonotherapy from 1990-1995." | 1.31 | Management of inoperable carcinoma of the breast by curative radiotherapy and chemo-hormonotherapy. ( Coupek, P; Filip, S; Petera, J; Slampa, P; Soumarová, R; Zatloukal, P, 2001) |
| "For women with metastatic breast cancer, complete remission is uncommon, and stable disease is a reasonable goal of successful therapy." | 1.31 | Successful management of breast cancer with liver metastases with medroxyprogesterone acetate treatment. ( Hara, Y; Hikosaka, Y; Iwase, H; Kobayashi, S; Toyama, T; Yamashita, H, 2001) |
| "Suspected pulmonary embolism was demonstrated by CT scan." | 1.31 | [Complicated antiphospholid antibody syndrome]. ( Eifrig, B; Hegewisch-Becker, S; Hossfeld, DK; Langer, F; Marx, G; Neuber, K, 2002) |
| "Measuring a bone resorption marker, ICTP, allows clinicians to monitor patients' responses to CAF therapy and may prevent prolonged ineffective therapy or unnecessary changes in therapy as a result of the flare phenomenon." | 1.30 | Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer. ( Koizumi, M; Matsumoto, S; Ogata, E; Takahashi, S; Yamashita, T, 1999) |
| "In stade II and III breast cancer, neoadjuvant chemotherapy with FEC-HD obtains an important histological response with an acceptable toxicity." | 1.30 | [Neoadjuvant chemotherapy FEC-HD in locally advanced breast cancer]. ( Arnoud, L; Belichard, C; Coudert, B; Darut-Jouve, A; Guerrin, J; Jolimoy, G, 1999) |
| "The prognosis of node negative breast cancer patients was mainly associated with tumor size." | 1.30 | [Prognosis and adjuvant chemotherapy of axillary node-negative breast cancer patients]. ( Han, Q; Shen, Z; Yu, L, 1997) |
| " Very little is known about the manner in which pharmacologic dosing of G-CSF may affect radiologic studies in vivo." | 1.29 | Changes in Tc-99m radionuclide bone scan images and peripheralization of marrow hematopoietic activity associated with the administration of granulocyte colony stimulating factor as an adjunct to dose-intensified chemotherapy for breast cancer. A case rep ( Demetri, GD; Kaplan, WD; Salgia, R, 1994) |
| "A 35-year-old female with inflammatory breast cancer was treated with preoperative intra-arterial infusion chemotherapy." | 1.29 | [A case of inflammatory breast cancer treated with preoperative intra-arterial infusion chemotherapy]. ( Matsuno, S; Migita, T; Saito, Y; Shibata, C; Shiiba, K, 1994) |
| "Because locally advanced infiltrating breast carcinomas are frequently diagnosed by fine-needle aspiration, histologic grade can be determined in the mastectomy specimens only after chemotherapy." | 1.29 | Histologic grade of locally advanced infiltrating ductal carcinoma after treatment with induction chemotherapy. ( Fechner, RE; Frierson, HF, 1994) |
| "Recent studies have revealed decreased pancreatic cancer cell growth upon administration of peptide YY (PYY)." | 1.29 | Adjuvant hormonal treatment with peptide YY or its analog decreases human pancreatic carcinoma growth. ( Balasubramaniam, A; Garvey, L; Liu, CD; McFadden, DW; Rongione, AJ, 1996) |
| "Thirteen (23%) of 56 women had no residual tumor." | 1.29 | Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy. ( Adler, DD; Cody, RL; Helvie, MA; Joynt, LK; Merajver, SD; Pierce, LJ, 1996) |
| "Patients with inflammatory breast cancer have a high risk of developing a local recurrence and/or distant metastases." | 1.29 | Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy. ( Arriagada, R; Fontaine, F; Le Chevalier, T; Mouriesse, H; Spielmann, M; Thomas, F; Tursz, T, 1995) |
| " From the dose-response curves, the 50% growth inhibition (IC50) level for each drug was estimated." | 1.29 | In vitro chemosensitivity of human pancreatic cancer cell lines. ( Oka, T; Sawabe, Y; Yamagishi, H; Yamaguchi, N; Yamamura, Y, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 45 (18.37) | 18.2507 |
| 2000's | 106 (43.27) | 29.6817 |
| 2010's | 92 (37.55) | 24.3611 |
| 2020's | 2 (0.82) | 2.80 |
| Authors | Studies |
|---|---|
| Shimmura, H | 1 |
| Kuramochi, H | 1 |
| Jibiki, N | 1 |
| Katagiri, S | 1 |
| Nishino, T | 1 |
| Araida, T | 1 |
| de Boo, L | 1 |
| Cimino-Mathews, A | 1 |
| Lubeck, Y | 1 |
| Daletzakis, A | 1 |
| Opdam, M | 1 |
| Sanders, J | 1 |
| Hooijberg, E | 1 |
| van Rossum, A | 1 |
| Loncova, Z | 1 |
| Rieder, D | 1 |
| Trajanoski, Z | 1 |
| Vollebergh, M | 1 |
| Sobral-Leite, M | 1 |
| van de Vijver, K | 1 |
| Broeks, A | 1 |
| van der Wiel, R | 1 |
| van Tinteren, H | 1 |
| Linn, S | 1 |
| Horlings, HM | 1 |
| Kok, M | 1 |
| Ishiguro, H | 1 |
| Masuda, N | 2 |
| Sato, N | 1 |
| Higaki, K | 1 |
| Morimoto, T | 1 |
| Yanagita, Y | 1 |
| Mizutani, M | 1 |
| Ohtani, S | 1 |
| Kaneko, K | 1 |
| Fujisawa, T | 1 |
| Takahashi, M | 1 |
| Kadoya, T | 1 |
| Matsunami, N | 1 |
| Yamamoto, Y | 3 |
| Ohno, S | 1 |
| Takano, T | 1 |
| Morita, S | 1 |
| Tanaka-Mizuno, S | 1 |
| Toi, M | 2 |
| Ludovini, V | 1 |
| Antognelli, C | 1 |
| Rulli, A | 1 |
| Foglietta, J | 1 |
| Pistola, L | 1 |
| Eliana, R | 1 |
| Floriani, I | 1 |
| Nocentini, G | 1 |
| Tofanetti, FR | 1 |
| Piattoni, S | 1 |
| Minenza, E | 1 |
| Talesa, VN | 1 |
| Sidoni, A | 1 |
| Tonato, M | 1 |
| Crinò, L | 1 |
| Gori, S | 2 |
| Chao, YL | 1 |
| Anders, CK | 1 |
| Khokher, S | 1 |
| Qureshi, MU | 1 |
| Mahmood, S | 1 |
| Nagi, AH | 1 |
| von Minckwitz, G | 5 |
| Möbus, V | 1 |
| Schneeweiss, A | 3 |
| Huober, J | 4 |
| Thomssen, C | 1 |
| Untch, M | 4 |
| Jackisch, C | 3 |
| Diel, IJ | 1 |
| Elling, D | 1 |
| Conrad, B | 1 |
| Kreienberg, R | 1 |
| Müller, V | 1 |
| Lück, HJ | 1 |
| Bauerfeind, I | 2 |
| Clemens, M | 1 |
| Schmidt, M | 1 |
| Noeding, S | 1 |
| Forstbauer, H | 1 |
| Barinoff, J | 1 |
| Belau, A | 1 |
| Nekljudova, V | 1 |
| Harbeck, N | 2 |
| Loibl, S | 5 |
| Di Lauro, L | 1 |
| Vici, P | 1 |
| Del Medico, P | 1 |
| Laudadio, L | 1 |
| Tomao, S | 1 |
| Giannarelli, D | 1 |
| Pizzuti, L | 1 |
| Sergi, D | 1 |
| Barba, M | 1 |
| Maugeri-Saccà, M | 1 |
| Mazouni, C | 2 |
| Naveau, A | 1 |
| Kane, A | 1 |
| Dunant, A | 2 |
| Garbay, JR | 1 |
| Leymarie, N | 1 |
| Sarfati, B | 1 |
| Delaloge, S | 1 |
| Rimareix, F | 1 |
| Riezzo, G | 2 |
| Clemente, C | 2 |
| Linsalata, M | 2 |
| D'Attoma, B | 2 |
| Orlando, A | 2 |
| Campanella, G | 2 |
| Giotta, F | 2 |
| Russo, F | 2 |
| Shimada, K | 2 |
| Ishikawa, T | 3 |
| Yoneyama, S | 1 |
| Kita, K | 1 |
| Narui, K | 2 |
| Sugae, S | 2 |
| Shimizu, D | 2 |
| Tanabe, M | 3 |
| Sasaki, T | 2 |
| Chishima, T | 1 |
| Ichikawa, Y | 2 |
| Endo, I | 2 |
| Rezai, M | 1 |
| Fasching, PA | 2 |
| Tesch, H | 2 |
| Hilfrich, J | 2 |
| Eidtmann, H | 3 |
| Gerber, B | 2 |
| Hanusch, C | 3 |
| Blohmer, JU | 1 |
| Costa, SD | 2 |
| Paepke, S | 1 |
| Kümmel, S | 2 |
| Denkert, C | 3 |
| Mehta, K | 2 |
| Lamberth, F | 1 |
| Guilbert, P | 1 |
| Gaillot-Petit, N | 1 |
| Champagne, C | 1 |
| Looten-Vieren, L | 1 |
| Nguyen, TD | 1 |
| Steger, GG | 1 |
| Greil, R | 1 |
| Lang, A | 1 |
| Rudas, M | 1 |
| Fitzal, F | 1 |
| Mlineritsch, B | 2 |
| Hartmann, BL | 1 |
| Bartsch, R | 1 |
| Melbinger, E | 1 |
| Hubalek, M | 1 |
| Stoeger, H | 1 |
| Dubsky, P | 1 |
| Ressler, S | 1 |
| Petzer, AL | 1 |
| Singer, CF | 1 |
| Muss, C | 1 |
| Jakesz, R | 2 |
| Gampenrieder, SP | 1 |
| Zielinski, CC | 1 |
| Fesl, C | 1 |
| Gnant, M | 2 |
| Kaczmarek, K | 1 |
| Wiącek, MP | 1 |
| Sulewski, A | 1 |
| Kubaszewski, Ł | 1 |
| Kaczmarczyk, J | 1 |
| Nowakowski, A | 1 |
| Prajoko, YW | 1 |
| Aryandono, T | 1 |
| Tiong, V | 1 |
| Rozita, AM | 1 |
| Taib, NA | 1 |
| Yip, CH | 1 |
| Ng, CH | 1 |
| Bozkurt, O | 1 |
| Berk, V | 1 |
| Kaplan, MA | 1 |
| Cetin, B | 1 |
| Ozaslan, E | 1 |
| Karaca, H | 1 |
| Inanc, M | 1 |
| Duran, AO | 1 |
| Ozkan, M | 1 |
| Bozovic-Spasojevic, I | 1 |
| Ameye, L | 1 |
| Paesmans, M | 1 |
| Larsimont, D | 1 |
| Di Leo, A | 1 |
| Dolci, S | 1 |
| Piccart, M | 1 |
| de Azambuja, E | 1 |
| Loi, S | 1 |
| Chan, MS | 1 |
| Chen, SF | 2 |
| Felizola, SJ | 1 |
| Wang, L | 1 |
| Nemoto, N | 1 |
| Tamaki, K | 1 |
| Ishida, T | 3 |
| Chow, LW | 2 |
| Ohuchi, N | 3 |
| Sasano, H | 2 |
| Das, U | 1 |
| Lakshmaiah, KC | 1 |
| Govind Babu, K | 1 |
| Suresh, TM | 1 |
| Lokanatha, D | 1 |
| Jacob, L | 1 |
| Babu, S | 1 |
| Satake, T | 1 |
| Adachi, S | 1 |
| Yamada, A | 1 |
| Kida, K | 1 |
| Horimoto, Y | 1 |
| Arakawa, A | 1 |
| Harada-Shoji, N | 1 |
| Sonoue, H | 1 |
| Yoshida, Y | 1 |
| Himuro, T | 1 |
| Igari, F | 1 |
| Tokuda, E | 1 |
| Mamat, O | 1 |
| Hino, O | 1 |
| Saito, M | 2 |
| Rashidi, A | 1 |
| Amarillo, I | 1 |
| Fisher, SI | 1 |
| Perrone, F | 1 |
| Nuzzo, F | 1 |
| Di Rella, F | 1 |
| Gravina, A | 1 |
| Iodice, G | 1 |
| Labonia, V | 1 |
| Landi, G | 1 |
| Pacilio, C | 1 |
| Rossi, E | 1 |
| De Laurentiis, M | 1 |
| D'Aiuto, M | 1 |
| Botti, G | 1 |
| Forestieri, V | 1 |
| Lauria, R | 1 |
| De Placido, S | 1 |
| Tinessa, V | 1 |
| Daniele, B | 1 |
| Colantuoni, G | 1 |
| Barni, S | 1 |
| Riccardi, F | 1 |
| De Maio, E | 1 |
| Montanino, A | 1 |
| Morabito, A | 2 |
| Daniele, G | 1 |
| Di Maio, M | 1 |
| Piccirillo, MC | 1 |
| Signoriello, S | 1 |
| Gallo, C | 1 |
| de Matteis, A | 1 |
| Mombelli, S | 1 |
| Kwiatkowski, F | 2 |
| Abrial, C | 1 |
| Wang-Lopez, Q | 1 |
| de Boissieu, P | 1 |
| Garbar, C | 1 |
| Bensussan, A | 1 |
| Curé, H | 2 |
| Gonzalez-Angulo, AM | 1 |
| Parinyanitikul, N | 1 |
| Lei, X | 1 |
| Mittendorf, EA | 1 |
| Zhang, H | 1 |
| Valero, V | 2 |
| Hunt, KK | 2 |
| Hortobagyi, GN | 4 |
| Chavez-MacGregor, M | 1 |
| Michishita, S | 1 |
| Kim, SJ | 2 |
| Shimazu, K | 2 |
| Sota, Y | 1 |
| Naoi, Y | 1 |
| Maruyama, N | 1 |
| Kagara, N | 1 |
| Shimoda, M | 1 |
| Shimomura, A | 1 |
| Noguchi, S | 3 |
| Peintinger, F | 1 |
| Sinn, B | 1 |
| Hatzis, C | 1 |
| Albarracin, C | 1 |
| Downs-Kelly, E | 1 |
| Morkowski, J | 1 |
| Gould, R | 1 |
| Symmans, WF | 2 |
| Mavroudis, D | 1 |
| Saloustros, E | 1 |
| Malamos, N | 1 |
| Kakolyris, S | 1 |
| Boukovinas, I | 1 |
| Papakotoulas, P | 1 |
| Kentepozidis, N | 1 |
| Ziras, N | 1 |
| Georgoulias, V | 1 |
| Gonçalves, A | 1 |
| Pierga, JY | 4 |
| Ferrero, JM | 1 |
| Mouret-Reynier, MA | 1 |
| Bachelot, T | 1 |
| Delva, R | 1 |
| Fabbro, M | 1 |
| Lerebours, F | 1 |
| Lotz, JP | 1 |
| Linassier, C | 1 |
| Dohollou, N | 1 |
| Eymard, JC | 1 |
| Leduc, B | 1 |
| Lemonnier, J | 1 |
| Martin, AL | 1 |
| Boher, JM | 1 |
| Viens, P | 1 |
| Roché, H | 2 |
| Al-Hameed, FM | 1 |
| de Oliveira, SF | 1 |
| Ganzinelli, M | 1 |
| Chilà, R | 1 |
| Serino, L | 1 |
| Maciel, ME | 1 |
| Urban, Cde A | 1 |
| de Lima, RS | 1 |
| Cavalli, IJ | 1 |
| Generali, D | 1 |
| Broggini, M | 1 |
| Damia, G | 1 |
| Ribeiro, EM | 1 |
| Redana, S | 1 |
| Sharp, A | 1 |
| Lote, H | 1 |
| Mohammed, K | 1 |
| Papadimitraki, E | 1 |
| Capelan, M | 1 |
| Ring, A | 1 |
| Alramadhan, M | 1 |
| Ryu, JM | 1 |
| Rayzah, M | 1 |
| Nam, SJ | 1 |
| Kim, SW | 2 |
| Yu, J | 2 |
| Lee, SK | 1 |
| Bae, SY | 1 |
| Park, S | 1 |
| Paik, HJ | 1 |
| Lee, JE | 2 |
| Ma, Y | 1 |
| Zhang, S | 1 |
| Zang, L | 1 |
| Li, J | 2 |
| Kang, Y | 1 |
| Ren, W | 1 |
| Schramm, A | 1 |
| Schochter, F | 1 |
| Friedl, TWP | 1 |
| de Gregorio, N | 1 |
| Andergassen, U | 1 |
| Alunni-Fabbroni, M | 1 |
| Trapp, E | 1 |
| Jaeger, B | 1 |
| Heinrich, G | 2 |
| Camara, O | 1 |
| Decker, T | 1 |
| Ober, A | 1 |
| Mahner, S | 1 |
| Fehm, TN | 1 |
| Pantel, K | 1 |
| Janni, W | 1 |
| Rack, BK | 1 |
| Ardavanis, A | 1 |
| Orphanos, G | 1 |
| Skafida, S | 1 |
| Basioukas, S | 1 |
| Rigatos, G | 1 |
| Goldsmith, YB | 1 |
| Roistacher, N | 1 |
| Baum, MS | 1 |
| Lázaro, A | 1 |
| Casinello, J | 1 |
| Amorós, A | 1 |
| Heredia, M | 1 |
| López-Alfonso, A | 1 |
| Kiba, T | 1 |
| Takeda, M | 1 |
| Matsuyama, K | 1 |
| Teramukai, S | 1 |
| Ishiwata, R | 1 |
| Takatsuka, Y | 1 |
| Ishioka, C | 1 |
| Fukushima, M | 1 |
| Chargari, C | 1 |
| Kirova, YM | 3 |
| Diéras, V | 4 |
| Castro Pena, P | 1 |
| Pena, PC | 1 |
| Campana, F | 1 |
| Cottu, PH | 1 |
| Pierga, J | 1 |
| Fourquet, A | 2 |
| Ghosal, N | 1 |
| Misra, V | 1 |
| Pérez-Alvarez, MJ | 1 |
| Arriola-Villalobos, P | 1 |
| Reche-Frutos, J | 1 |
| García-Sánchez, J | 1 |
| Boidot, R | 2 |
| Vegran, F | 2 |
| Soubeyrand, MS | 1 |
| Fumoleau, P | 1 |
| Coudert, B | 2 |
| Lizard-Nacol, S | 2 |
| Manga, GP | 1 |
| Shahi, PK | 1 |
| Ureña, MM | 1 |
| Pereira, RQ | 1 |
| Plaza, MI | 1 |
| Peron, YI | 1 |
| Val, RG | 1 |
| Carrión, JB | 1 |
| Cañón, EP | 1 |
| Alfonso, PG | 1 |
| Alvarado-Miranda, A | 1 |
| Arrieta, O | 1 |
| Gamboa-Vignolle, C | 1 |
| Saavedra-Perez, D | 1 |
| Morales-Barrera, R | 1 |
| Bargallo-Rocha, E | 1 |
| Zinser-Sierra, J | 1 |
| Perez-Sanchez, V | 1 |
| Ramirez-Ugalde, T | 1 |
| Lara-Medina, F | 1 |
| Loo, WT | 1 |
| Suzuki, T | 2 |
| Ono, K | 1 |
| Hirakawa, H | 1 |
| Wang, B | 1 |
| Fu, JF | 1 |
| Hong, ZW | 1 |
| Cathomas, R | 1 |
| von Moos, R | 1 |
| Aleskandarany, MA | 1 |
| Green, AR | 1 |
| Rakha, EA | 1 |
| Mohammed, RA | 1 |
| Elsheikh, SE | 1 |
| Powe, DG | 1 |
| Paish, EC | 1 |
| Macmillan, RD | 1 |
| Chan, S | 1 |
| Ahmed, SI | 1 |
| Ellis, IO | 1 |
| Livi, L | 1 |
| Saieva, C | 1 |
| Borghesi, S | 1 |
| De Luca Cardillo, C | 1 |
| Scotti, V | 1 |
| Mangoni, M | 1 |
| Greto, D | 1 |
| Cataliotti, L | 1 |
| Paiar, F | 1 |
| Bianchi, S | 1 |
| Biti, GP | 1 |
| Baena-Cañada, JM | 1 |
| Martínez, MJ | 1 |
| García-Olmedo, O | 1 |
| Jiménez-Bárcenas, R | 1 |
| Muriel-Cueto, P | 1 |
| Matsui, H | 1 |
| Nagashima, A | 1 |
| Kawaoka, T | 1 |
| Hiraki, S | 1 |
| Fukuda, S | 1 |
| Ronneburg, H | 1 |
| Span, PN | 1 |
| Kantelhardt, E | 1 |
| Dittmer, A | 1 |
| Schunke, D | 1 |
| Holzhausen, HJ | 1 |
| Sweep, FC | 1 |
| Dittmer, J | 1 |
| Konishi, K | 1 |
| Hasegawa, N | 1 |
| Kaneko, H | 1 |
| Iimura, Y | 1 |
| Shoji, Y | 1 |
| Kawabata, M | 1 |
| Afsar, NA | 1 |
| Haenisch, S | 1 |
| Mateen, A | 1 |
| Usman, A | 1 |
| Ufer, M | 1 |
| Ahmed, KZ | 1 |
| Ahmad, HR | 1 |
| Cascorbi, I | 1 |
| Geddes, ER | 1 |
| Cohen, PR | 1 |
| Recchia, F | 2 |
| Candeloro, G | 1 |
| Necozione, S | 1 |
| Accorsi, P | 1 |
| Recchia, CO | 1 |
| Tombolini, V | 1 |
| Rea, S | 1 |
| Macková, D | 1 |
| Takada, M | 1 |
| Terunuma, H | 1 |
| Deng, X | 1 |
| Dewan, MZ | 1 |
| Saji, S | 1 |
| Kuroi, K | 1 |
| Yamamoto, N | 1 |
| Kefeli, U | 1 |
| Bilici, A | 1 |
| Ustaalioglu, BB | 1 |
| Kefeli, AU | 1 |
| Yildirim, ME | 1 |
| Seker, M | 1 |
| Gumus, M | 1 |
| Anyanwu, SN | 1 |
| Nwose, P | 1 |
| Ihekwoaba, E | 1 |
| Mbaeri, AT | 1 |
| Chukwuanukwu, TO | 1 |
| Jung, M | 1 |
| Shin, HJ | 2 |
| Rha, SY | 3 |
| Jeung, HC | 2 |
| Hong, S | 1 |
| Moon, YW | 2 |
| Kim, HS | 1 |
| Oh, KJ | 1 |
| Yang, WI | 2 |
| Roh, JK | 2 |
| Chung, HC | 3 |
| Oliveira, AL | 1 |
| Rodrigues, FF | 1 |
| Santos, RE | 1 |
| Aoki, T | 1 |
| Rocha, MN | 1 |
| Longui, CA | 1 |
| Melo, MB | 1 |
| Hatam, N | 1 |
| Ahmadloo, N | 1 |
| Ahmad Kia Daliri, A | 1 |
| Bastani, P | 1 |
| Askarian, M | 1 |
| Petit, T | 2 |
| Wilt, M | 1 |
| Velten, M | 2 |
| Rodier, JF | 2 |
| Fricker, JP | 1 |
| Dufour, P | 2 |
| Ghnassia, JP | 1 |
| Tabchy, A | 1 |
| Vidaurre, T | 1 |
| Lluch, A | 3 |
| Gomez, H | 1 |
| Martin, M | 2 |
| Qi, Y | 1 |
| Barajas-Figueroa, LJ | 1 |
| Souchon, E | 1 |
| Coutant, C | 1 |
| Doimi, FD | 1 |
| Ibrahim, NK | 1 |
| Gong, Y | 1 |
| Hess, KR | 1 |
| Pusztai, L | 2 |
| Nakamura, Y | 2 |
| Aono, T | 1 |
| Nomura, M | 1 |
| Iwase, K | 1 |
| Tanaka, Y | 2 |
| Leyder, M | 1 |
| Laubach, M | 1 |
| Breugelmans, M | 1 |
| Keymolen, K | 1 |
| De Greve, J | 1 |
| Foulon, W | 1 |
| Ikeda, M | 1 |
| Sonoo, H | 1 |
| Oota, Y | 1 |
| Fujii, S | 1 |
| Shimo, T | 1 |
| Miyake, A | 1 |
| Seki, M | 1 |
| Nomura, T | 1 |
| Shiiki, S | 1 |
| Nakashima, K | 1 |
| Tanaka, K | 1 |
| Kurebayashi, J | 1 |
| Noske, A | 1 |
| Darb-Esfahani, S | 2 |
| Roller, M | 1 |
| Kronenwett, R | 1 |
| Müller, BM | 1 |
| Steffen, J | 1 |
| von Toerne, C | 1 |
| Wirtz, R | 1 |
| Baumann, I | 1 |
| Hoffmann, G | 2 |
| Grasshoff, ST | 1 |
| Ulmer, HU | 1 |
| Kashiwagi, S | 1 |
| Kawajiri, H | 1 |
| Noda, S | 1 |
| Takashima, T | 1 |
| Onoda, N | 1 |
| Nakata, B | 1 |
| Kato, Y | 1 |
| Hirakawa, K | 1 |
| Rosenberg, M | 1 |
| Castagno, A | 1 |
| Nadal, J | 1 |
| Rosales, A | 1 |
| Pueyrredon, EP | 1 |
| Patané, AK | 1 |
| Bourgier, C | 1 |
| Pessoa, EL | 1 |
| Heymann, S | 1 |
| Spielmann, M | 3 |
| Uzan, C | 1 |
| Mathieu, MC | 1 |
| Arriagada, R | 2 |
| Marsiglia, H | 1 |
| Yagata, H | 2 |
| Kajiura, Y | 1 |
| Yamauchi, H | 1 |
| DI, Lj | 1 |
| Song, Gh | 1 |
| Che, L | 1 |
| Jiang, Hf | 1 |
| Zhu, Yl | 1 |
| Liang, X | 1 |
| Jia, J | 1 |
| Zhang, J | 2 |
| Yang, Hb | 1 |
| Wang, Xl | 1 |
| Zhou, Xn | 1 |
| Ren, J | 1 |
| Sawaki, M | 1 |
| Tokudome, N | 1 |
| Mizuno, T | 1 |
| Nakayama, T | 1 |
| Taira, N | 3 |
| Bando, H | 1 |
| Murakami, S | 1 |
| Kashiwaba, M | 1 |
| Iwata, H | 1 |
| Uemura, Y | 1 |
| Ohashi, Y | 1 |
| Le Tourneau, C | 1 |
| Dettwiler, S | 1 |
| Beuzeboc, P | 2 |
| Alran, S | 1 |
| Laurence, V | 2 |
| Fréneaux, P | 1 |
| Sigal-Zafrani, B | 2 |
| Vincent-Salomon, A | 2 |
| Glück, S | 1 |
| Ross, JS | 1 |
| Royce, M | 1 |
| McKenna, EF | 1 |
| Perou, CM | 2 |
| Avisar, E | 1 |
| Wu, L | 1 |
| Lin, PH | 1 |
| Chiu, CF | 1 |
| Lu, YS | 1 |
| Gilje, B | 1 |
| Nordgård, O | 1 |
| Tjensvoll, K | 1 |
| Janssen, EA | 1 |
| Søiland, H | 1 |
| Smaaland, R | 1 |
| Baak, JP | 1 |
| Shipman, KE | 1 |
| Arnold, I | 1 |
| Delpeuch, A | 1 |
| Leveque, D | 1 |
| Rob, L | 1 |
| Bergerat, JP | 2 |
| Solbach, C | 1 |
| Holms, F | 1 |
| Dietrich, K | 1 |
| Just, M | 1 |
| Clemens, MR | 1 |
| Schrader, I | 1 |
| Henschen, S | 1 |
| Tiemann, K | 1 |
| Diebold, K | 1 |
| Nikolényi, A | 1 |
| Sükösd, F | 1 |
| Kaizer, L | 1 |
| Csörgo, E | 1 |
| Vörös, A | 1 |
| Uhercsák, G | 1 |
| Ormándi, K | 1 |
| Lázár, G | 1 |
| Thurzó, L | 1 |
| Brodowicz, T | 1 |
| Kahán, Z | 1 |
| Ikeda, H | 1 |
| Nogami, T | 1 |
| Shien, K | 1 |
| Okada, M | 1 |
| Shien, T | 1 |
| Doihara, H | 2 |
| Miyoshi, S | 1 |
| Nakayama, S | 1 |
| Tamaki, Y | 1 |
| Akazawa, K | 1 |
| Tsukamoto, F | 1 |
| Torikoshi, Y | 1 |
| Matsushima, T | 1 |
| Shibayama, M | 1 |
| Ishihara, H | 1 |
| Gong, C | 1 |
| Luo, M | 1 |
| Yao, HR | 1 |
| Zeng, YJ | 1 |
| Su, FX | 1 |
| Farias, JW | 1 |
| Furtado, FS | 1 |
| Guimarães, SB | 1 |
| Silva Filho, AR | 1 |
| Vasconcelos, PR | 1 |
| Zapf, I | 1 |
| Tizedes, G | 1 |
| Pavlovics, G | 1 |
| Kovács, G | 1 |
| Kálmán, E | 1 |
| Szalai, G | 1 |
| Kövér, E | 1 |
| Farkas, R | 1 |
| Horváth, OP | 1 |
| Chen, S | 2 |
| Chen, CM | 2 |
| Yu, KD | 2 |
| Yang, WT | 1 |
| Shao, ZM | 3 |
| Liu, ZZ | 1 |
| Lu, ZD | 1 |
| Zhang, HW | 1 |
| Yang, H | 1 |
| Liu, H | 1 |
| Li, LF | 2 |
| Li, WL | 1 |
| Cui, SD | 1 |
| Joensuu, H | 1 |
| Kellokumpu-Lehtinen, PL | 1 |
| Huovinen, R | 1 |
| Jukkola-Vuorinen, A | 1 |
| Tanner, M | 1 |
| Kokko, R | 1 |
| Ahlgren, J | 1 |
| Auvinen, P | 1 |
| Paija, O | 1 |
| Helle, L | 1 |
| Villman, K | 1 |
| Nyandoto, P | 1 |
| Nilsson, G | 1 |
| Pajunen, M | 1 |
| Asola, R | 1 |
| Poikonen, P | 1 |
| Leinonen, M | 1 |
| Kataja, V | 1 |
| Bono, P | 1 |
| Lindman, H | 1 |
| Sato, T | 1 |
| Nakagawa, T | 1 |
| Kuwayama, T | 1 |
| Oda, G | 1 |
| Sugimoto, H | 1 |
| Ishiba, T | 1 |
| Sugihara, K | 1 |
| Karasawa, K | 1 |
| Hirowatari, H | 1 |
| Izawa, H | 1 |
| Furuya, T | 1 |
| Ozawa, S | 1 |
| Ito, K | 1 |
| Mitsuhashi, N | 1 |
| Zhou, RJ | 1 |
| Massabeau, C | 1 |
| Belin, L | 1 |
| Savignoni, A | 1 |
| Richardson, M | 1 |
| Cohen-Jonathan-Moyal, E | 1 |
| Mégnin-Chanet, F | 1 |
| Hall, J | 1 |
| Gonzalez-Perez, LM | 1 |
| Infante-Cossio, P | 1 |
| Crespo-Torres, S | 1 |
| Sanchez-Gallego, F | 1 |
| Jacot, W | 1 |
| Pouderoux, S | 1 |
| Thezenas, S | 1 |
| Chapelle, A | 1 |
| Bleuse, JP | 1 |
| Romieu, G | 1 |
| Lamy, PJ | 1 |
| Wang, LZ | 1 |
| Ouyang, T | 1 |
| Wang, TF | 1 |
| Xie, YT | 1 |
| Fan, ZQ | 1 |
| Fan, T | 1 |
| Lin, BY | 1 |
| Li, JF | 1 |
| Villarini, A | 1 |
| Pasanisi, P | 1 |
| Raimondi, M | 1 |
| Gargano, G | 1 |
| Bruno, E | 1 |
| Morelli, D | 1 |
| Evangelista, A | 1 |
| Curtosi, P | 1 |
| Berrino, F | 1 |
| Jacob, J | 1 |
| Fourchotte, V | 1 |
| Bollet, MA | 1 |
| Kontani, K | 1 |
| Kuroda, N | 1 |
| Hashimoto, S | 1 |
| Murazawa, C | 1 |
| Norimura, S | 1 |
| Tanaka, H | 1 |
| Ohtani, M | 1 |
| Fujiwara-Honjo, N | 1 |
| Kushida, Y | 1 |
| Date, M | 1 |
| Haba, R | 1 |
| Houchi, H | 1 |
| Yamauchi, A | 1 |
| Yokomise, H | 1 |
| Bonneterre, J | 2 |
| Révillion, F | 1 |
| Desauw, C | 1 |
| Blot, E | 1 |
| Kramar, A | 1 |
| Fournier, C | 1 |
| Hornez, L | 1 |
| Peyrat, JP | 1 |
| Barrick, B | 1 |
| Matthys, B | 1 |
| Fraga, G | 1 |
| Takahashi, R | 1 |
| Fujii, T | 2 |
| Inoue, Y | 1 |
| Takahashi, H | 2 |
| Akashi, M | 1 |
| Nishida, R | 1 |
| Takami, Y | 1 |
| Saitsu, H | 1 |
| Momosaki, S | 1 |
| Nakayama, Y | 1 |
| Uchino, K | 1 |
| Takayoshi, K | 1 |
| Shirouzu, K | 2 |
| Silva, LM | 1 |
| Takahashi, CS | 1 |
| Carrara, HH | 1 |
| Parton, M | 1 |
| Krajewski, S | 1 |
| Smith, I | 1 |
| Krajewska, M | 1 |
| Archer, C | 1 |
| Naito, M | 1 |
| Ahern, R | 1 |
| Reed, J | 1 |
| Dowsett, M | 1 |
| Nichols, G | 1 |
| de Castro, K | 1 |
| Wei, LX | 1 |
| Griffin, M | 1 |
| Lin, N | 1 |
| Oratzi, A | 1 |
| Murty, VV | 1 |
| Troxel, A | 1 |
| Vahdat, L | 1 |
| Hesdorffer, C | 1 |
| Sivelli, R | 1 |
| Del Rio, P | 1 |
| Arcuri, MF | 1 |
| Corcione, L | 1 |
| Moreno, A | 1 |
| Escobedo, A | 1 |
| Benito, E | 1 |
| Serra, JM | 1 |
| Gumà, A | 1 |
| Riu, F | 1 |
| Weldon, CB | 1 |
| Jaffe, BM | 1 |
| Kahn, MJ | 1 |
| Abali, H | 1 |
| Celik, I | 1 |
| Anan, K | 1 |
| Mitsuyama, S | 1 |
| Tamae, K | 1 |
| Suehara, N | 1 |
| Nishihara, K | 1 |
| Ogawa, Y | 2 |
| Abe, Y | 1 |
| Iwashita, T | 1 |
| Toyoshima, S | 1 |
| Harris, EE | 1 |
| Schultz, D | 1 |
| Bertsch, H | 1 |
| Fox, K | 1 |
| Glick, J | 1 |
| Solin, LJ | 1 |
| Cocquyt, VF | 1 |
| Blondeel, PN | 1 |
| Depypere, HT | 1 |
| Praet, MM | 1 |
| Schelfhout, VR | 1 |
| Silva, OE | 1 |
| Hurley, J | 1 |
| Serreyn, RF | 1 |
| Daems, KK | 1 |
| Van Belle, SJ | 1 |
| Ploner, F | 1 |
| Hausmaninger, H | 1 |
| Kolb, R | 1 |
| Stierer, M | 1 |
| Fridrik, M | 1 |
| Steindorfer, P | 1 |
| Haider, K | 1 |
| Tschurtschenthaler, G | 1 |
| Steger, G | 1 |
| Seifert, M | 1 |
| Kubista, E | 1 |
| Samonigg, H | 1 |
| Chen, CA | 1 |
| Chen, M | 1 |
| Giglio, P | 1 |
| Tremont-Lukats, IW | 1 |
| Groves, MD | 1 |
| Ernst, MF | 1 |
| Voogd, AC | 1 |
| Coebergh, JW | 1 |
| Poortmans, PM | 1 |
| Roukema, JA | 1 |
| Rai, Y | 2 |
| Sagara, Y | 5 |
| Ooi, Y | 2 |
| Gül, U | 1 |
| Kiliç, A | 1 |
| Tamaru, N | 1 |
| Hishikawa, Y | 1 |
| Ejima, K | 1 |
| Nagasue, N | 1 |
| Inoue, S | 1 |
| Muramatsu, M | 1 |
| Hayashi, T | 1 |
| Koji, T | 1 |
| Abe, H | 1 |
| Hanasawa, K | 1 |
| Naitoh, H | 1 |
| Endo, Y | 1 |
| Tani, T | 1 |
| Kushima, R | 1 |
| Lemos, LB | 1 |
| Qu, Z | 1 |
| Garg, K | 1 |
| Papasozomenos, S | 1 |
| Zhao, J | 1 |
| Wu, YL | 1 |
| Wang, YD | 1 |
| Zhao, GR | 1 |
| Wang, J | 1 |
| Terazaki, Y | 1 |
| Nagamatsu, H | 1 |
| Ono, H | 1 |
| Iwakuma, N | 1 |
| Brunello, A | 1 |
| Basso, U | 1 |
| Pogliani, C | 1 |
| Jirillo, A | 1 |
| Ghiotto, C | 1 |
| Koussis, H | 1 |
| Lumachi, F | 1 |
| Iacobone, M | 1 |
| Vamvakas, L | 1 |
| Monfardini, S | 1 |
| Yu, Z | 1 |
| Sun, J | 1 |
| Zhen, J | 1 |
| Zhang, Q | 2 |
| Yang, Q | 2 |
| Hikino, H | 1 |
| Yamada, T | 1 |
| Johbara, K | 1 |
| Obayashi, N | 1 |
| Ozaki, N | 1 |
| Mathelin, C | 1 |
| Annane, K | 1 |
| Liegeois, P | 1 |
| Suh, CO | 1 |
| Cold, S | 1 |
| Düring, M | 1 |
| Ewertz, M | 1 |
| Knoop, A | 1 |
| Møller, S | 1 |
| Kara, IO | 1 |
| Sahin, B | 1 |
| Erkisi, M | 1 |
| Di Costanzo, F | 1 |
| Gasperoni, S | 1 |
| Papaldo, P | 1 |
| Bilancia, D | 1 |
| Manzione, L | 1 |
| Landucci, E | 1 |
| Mazzoni, F | 1 |
| Cognetti, F | 1 |
| Altinyollar, H | 1 |
| Dingil, G | 1 |
| Berberoglu, U | 1 |
| He, J | 1 |
| Feng, FY | 1 |
| Xing, PY | 1 |
| Wang, XY | 1 |
| Zhang, P | 1 |
| Marutaka, M | 1 |
| Suguri, T | 1 |
| Miyake, M | 1 |
| Yoshimura, K | 1 |
| Namer, M | 1 |
| Fargeot, P | 1 |
| Campone, M | 1 |
| Kerbrat, P | 1 |
| Romestaing, P | 1 |
| Monnier, A | 1 |
| Luporsi, E | 1 |
| Montcuquet, P | 1 |
| Asproudis, I | 1 |
| Gorezis, S | 1 |
| Stefaniotou, M | 1 |
| Peschos, D | 1 |
| Psilas, K | 1 |
| Higa, GM | 1 |
| Kovach, RF | 1 |
| Abraham, J | 1 |
| Han, W | 1 |
| Han, MR | 1 |
| Kang, JJ | 1 |
| Bae, JY | 1 |
| Lee, JH | 1 |
| Bae, YJ | 1 |
| Hwang, KT | 1 |
| Hwang, SE | 1 |
| Noh, DY | 1 |
| Sestito, A | 1 |
| Sgueglia, GA | 1 |
| Pozzo, C | 1 |
| Cassano, A | 1 |
| Barone, C | 1 |
| Crea, F | 1 |
| Lanza, GA | 1 |
| Aogi, K | 2 |
| Ohsumi, S | 1 |
| Takashima, S | 1 |
| Nishimura, R | 1 |
| Saeki, T | 2 |
| Tham, YL | 1 |
| Hinckley, L | 1 |
| Teh, BS | 1 |
| Elledge, R | 1 |
| Malamou-Mitsi, V | 1 |
| Gogas, H | 1 |
| Dafni, U | 1 |
| Bourli, A | 1 |
| Fillipidis, T | 1 |
| Sotiropoulou, M | 1 |
| Vlachodimitropoulos, D | 1 |
| Papadopoulos, S | 1 |
| Tzaida, O | 1 |
| Kafiri, G | 1 |
| Kyriakou, V | 1 |
| Markaki, S | 1 |
| Papaspyrou, I | 1 |
| Karagianni, E | 1 |
| Pavlakis, K | 1 |
| Toliou, T | 1 |
| Scopa, C | 1 |
| Papakostas, P | 1 |
| Bafaloukos, D | 1 |
| Christodoulou, C | 1 |
| Fountzilas, G | 1 |
| Oudin, C | 1 |
| Riedinger, JM | 1 |
| Bonnetain, F | 1 |
| Yoshidome, K | 1 |
| Imabun, S | 1 |
| Nakahara, M | 1 |
| Hiraoka, K | 1 |
| Yamagami, Y | 1 |
| Tsujimoto, M | 1 |
| Nakao, K | 1 |
| Kaufmann, P | 1 |
| Dauphine, CE | 1 |
| Vargas, MP | 1 |
| Burla, ML | 1 |
| Isaac, NM | 1 |
| Gonzalez, KD | 1 |
| Rosing, D | 1 |
| Vargas, HI | 1 |
| Maciá Escalante, S | 1 |
| Rodríguez Lescure, A | 1 |
| Pons Sanz, V | 1 |
| Martínez Banaclocha, N | 2 |
| Guillén Ponce, C | 1 |
| Carrato Mena, A | 1 |
| Guedin, P | 1 |
| Chasle, J | 1 |
| Blanc-Fournier, C | 1 |
| Lacroix, J | 1 |
| Karakuzu, A | 1 |
| Koc, M | 1 |
| Ozdemir, S | 1 |
| Sørlie, T | 1 |
| Fan, C | 1 |
| Geisler, S | 1 |
| Aas, T | 1 |
| Nobel, A | 1 |
| Anker, G | 1 |
| Akslen, LA | 1 |
| Botstein, D | 1 |
| Børresen-Dale, AL | 1 |
| Lønning, PE | 1 |
| Merck, B | 1 |
| Cansado Martínez, P | 1 |
| Pérez Ramos, M | 1 |
| Lacueva Gómez, FJ | 1 |
| Calpena, R | 1 |
| Hall, A | 1 |
| Broglio, K | 1 |
| Fritsche, H | 1 |
| Andre, F | 1 |
| Esteva, FJ | 1 |
| Buzdar, AU | 2 |
| Cristofanilli, M | 1 |
| Suzuki, M | 1 |
| Tamada, S | 1 |
| Tsuchimochi, S | 1 |
| Takahama, T | 1 |
| Matsuyama, Y | 1 |
| Ando, M | 1 |
| Sahin, FI | 1 |
| Yilmaz, Z | 1 |
| Karakuş, S | 1 |
| Boğa, S | 1 |
| Akçali, Z | 1 |
| DemIrhan, B | 1 |
| Shen, J | 1 |
| Gilcrease, MZ | 1 |
| Babiera, GV | 1 |
| Ross, MI | 1 |
| Meric-Bernstam, F | 1 |
| Feig, BW | 1 |
| Kuerer, HM | 1 |
| Francis, A | 1 |
| Ames, FC | 1 |
| Zhang, B | 1 |
| Zhao, L | 1 |
| Long, F | 1 |
| Li, S | 1 |
| Jiang, DQ | 1 |
| Xu, H | 1 |
| Wang, XX | 1 |
| Zhou, ZM | 1 |
| Yuan, ZY | 1 |
| Zhang, DS | 1 |
| Shi, YX | 1 |
| Jiang, WQ | 1 |
| Fontana, S | 1 |
| Ghilardi, R | 1 |
| Barbaglio, A | 1 |
| Amaddeo, P | 1 |
| Faldi, F | 1 |
| Pericotti, S | 1 |
| Perez-Fidalgo, JA | 1 |
| Chirivella, I | 1 |
| Laforga, J | 1 |
| Colio, JM | 1 |
| Blanes, MD | 1 |
| Baydal, R | 1 |
| Roselló, S | 1 |
| De-la-Morena, E | 1 |
| Koda, M | 1 |
| Sulkowska, M | 1 |
| Kanczuga-Koda, L | 1 |
| Tomaszewski, J | 1 |
| Kucharczuk, W | 1 |
| Lesniewicz, T | 1 |
| Cymek, S | 1 |
| Sulkowski, S | 1 |
| Bo, Y | 1 |
| Li, HS | 1 |
| Qi, YC | 1 |
| Lu, MY | 1 |
| Lin, CS | 1 |
| Lin, SH | 1 |
| Chiang, YH | 1 |
| Sheu, LF | 1 |
| Chao, TY | 1 |
| Morohashi, S | 1 |
| Odagiri, H | 1 |
| Morohashi, H | 1 |
| Kimura, Y | 1 |
| Sasaki, M | 2 |
| Chen, L | 1 |
| Fan, Y | 1 |
| Lang, RG | 1 |
| Guo, XJ | 1 |
| Sun, YL | 1 |
| Fu, L | 1 |
| Genet, D | 1 |
| Lejeune, C | 1 |
| Bonnier, P | 1 |
| Aubard, Y | 1 |
| Venat-Bouvet, L | 1 |
| Adjadj, DJ | 1 |
| Martin, J | 1 |
| Labourey, JL | 1 |
| Benyoub, A | 1 |
| Clavère, P | 1 |
| Lebrun-Ly, V | 1 |
| Juin, P | 1 |
| Piana, L | 1 |
| Tubiana-Mathieu, N | 1 |
| Xue, Y | 1 |
| Guo, XT | 1 |
| Liu, WC | 1 |
| Iida, S | 1 |
| Furukawa, K | 1 |
| Yokoyama, T | 1 |
| Yanagihara, K | 1 |
| Iwasaki, R | 1 |
| Noguchi, T | 1 |
| Tsuchiya, S | 1 |
| Sugisaki, Y | 1 |
| Naito, Z | 1 |
| Tajiri, T | 1 |
| McLean, SR | 1 |
| Shousha, S | 1 |
| Francis, N | 1 |
| Lim, A | 1 |
| Eccles, S | 1 |
| Nathan, M | 1 |
| Brock, CS | 1 |
| Palmieri, C | 1 |
| Sánchez-Suárez, P | 1 |
| Ostrosky-Wegman, P | 1 |
| Gallegos-Hernández, F | 1 |
| Peñarroja-Flores, R | 1 |
| Toledo-García, J | 1 |
| Bravo, JL | 1 |
| Del Castillo, ER | 1 |
| Benítez-Bribiesca, L | 1 |
| Xu, XJ | 1 |
| Zhao, Y | 1 |
| Liu, ZB | 1 |
| Shen, ZZ | 1 |
| Jin, WR | 1 |
| Tsunoda-Shimizu, H | 1 |
| Hayashi, N | 1 |
| Hamaoka, T | 1 |
| Kawasaki, T | 1 |
| Tsugawa, K | 1 |
| Kikuchi, M | 1 |
| Suzuki, K | 1 |
| Nakamura, S | 1 |
| Jain, S | 1 |
| Agarwal, JP | 1 |
| Gupta, T | 1 |
| Parikh, PM | 1 |
| Mistry, RC | 1 |
| Menon, H | 1 |
| Pramesh, CS | 1 |
| Shrivastava, SK | 1 |
| Pant, S | 1 |
| Landon, MB | 1 |
| Blumenfeld, M | 1 |
| Farrar, W | 1 |
| Shapiro, CL | 1 |
| Hui, R | 1 |
| Zhang, M | 1 |
| Hao, XM | 1 |
| Vogel, P | 1 |
| Kaufmann, M | 1 |
| Shigekawa, T | 1 |
| Takeuchi, H | 1 |
| Misumi, M | 1 |
| Matsuura, K | 1 |
| Sano, H | 1 |
| Fujiuchi, N | 1 |
| Okubo, K | 1 |
| Osaki, A | 1 |
| Rodríguez-Lescure, A | 1 |
| Ruiz, A | 1 |
| Alba, E | 1 |
| Calvo, L | 1 |
| Ruiz-Borrego, M | 1 |
| Munárriz, B | 1 |
| Rodríguez, CA | 1 |
| Crespo, C | 1 |
| de Alava, E | 1 |
| López García-Asenjo, JA | 1 |
| Guitián, MD | 1 |
| Almenar, S | 1 |
| González-Palacios, JF | 1 |
| Vera, F | 1 |
| Palacios, J | 1 |
| Ramos, M | 1 |
| Gracia Marco, JM | 1 |
| Alvarez, I | 1 |
| Seguí, MA | 1 |
| Mayordomo, JI | 1 |
| Antón, A | 1 |
| Baena, JM | 1 |
| Plazaola, A | 1 |
| Modolell, A | 1 |
| Pelegrí, A | 1 |
| Mel, JR | 1 |
| Aranda, E | 1 |
| Adrover, E | 1 |
| Alvarez, JV | 1 |
| García Puche, JL | 1 |
| Sánchez-Rovira, P | 1 |
| Gonzalez, S | 1 |
| López-Vega, JM | 1 |
| Vergeylen, A | 1 |
| Klöppel, G | 1 |
| Pache, L | 1 |
| Eiermann, W | 1 |
| Salgia, R | 1 |
| Demetri, GD | 1 |
| Kaplan, WD | 1 |
| Hofmann, M | 1 |
| Mahlke, M | 1 |
| Casper, F | 1 |
| Brockerhoff, P | 1 |
| Prager, D | 1 |
| Grundfest-Broniatowski, S | 1 |
| Lerner, HJ | 1 |
| Margolese, RG | 1 |
| Dimitrov, N | 1 |
| Silverman, P | 1 |
| Takahashi, N | 1 |
| Nitta, A | 1 |
| Kunii, Y | 1 |
| Ota, K | 1 |
| Tolcher, AW | 1 |
| Giusti, RM | 1 |
| O'Shaughnessy, JA | 2 |
| Cowan, KH | 2 |
| Migita, T | 1 |
| Shiiba, K | 1 |
| Saito, Y | 1 |
| Shibata, C | 1 |
| Matsuno, S | 1 |
| Frierson, HF | 1 |
| Fechner, RE | 1 |
| Calais, G | 1 |
| Berger, C | 1 |
| Descamps, P | 1 |
| Chapet, S | 1 |
| Reynaud-Bougnoux, A | 1 |
| Body, G | 1 |
| Bougnoux, P | 1 |
| Lansac, J | 1 |
| Le Floch, O | 1 |
| Chen, JA | 1 |
| Ohmori, Y | 1 |
| Toki, T | 1 |
| Okazaki, Y | 1 |
| Ogoshi, S | 1 |
| Singh, G | 1 |
| Singh, DP | 1 |
| Gupta, D | 1 |
| Muralikrishna, BV | 1 |
| Liu, CD | 1 |
| Rongione, AJ | 1 |
| Garvey, L | 1 |
| Balasubramaniam, A | 1 |
| McFadden, DW | 1 |
| Helvie, MA | 1 |
| Joynt, LK | 1 |
| Cody, RL | 1 |
| Pierce, LJ | 1 |
| Adler, DD | 1 |
| Merajver, SD | 1 |
| Pekarske, SL | 1 |
| Shin, SS | 1 |
| Thomas, F | 1 |
| Mouriesse, H | 1 |
| Le Chevalier, T | 1 |
| Fontaine, F | 1 |
| Tursz, T | 1 |
| DiPaola, RS | 1 |
| Kaufman, A | 1 |
| Mikhail, MM | 1 |
| van Slooten, HJ | 1 |
| Clahsen, PC | 1 |
| van Dierendonck, JH | 1 |
| Duval, C | 1 |
| Pallud, C | 1 |
| Mandard, AM | 1 |
| Delobelle-Deroide, A | 1 |
| van de Velde, CJ | 1 |
| van de Vijver, MJ | 1 |
| Tsuji, Y | 1 |
| Ohigashi, H | 1 |
| Ishikawa, O | 1 |
| Yasuda, T | 1 |
| Nakano, H | 1 |
| Nakamori, S | 1 |
| Kameyama, M | 1 |
| Hiratsuka, M | 1 |
| Sasaki, Y | 1 |
| Kabuto, T | 1 |
| Furukawa, H | 1 |
| Imaoka, S | 1 |
| Iwanaga, T | 1 |
| Sawabe, Y | 1 |
| Yamagishi, H | 1 |
| Yamaguchi, N | 1 |
| Yamamura, Y | 1 |
| Oka, T | 1 |
| Kim, JH | 1 |
| Min, JS | 1 |
| Lee, KS | 1 |
| Kim, BS | 1 |
| Lee, KB | 1 |
| Willers, H | 1 |
| Würschmidt, F | 1 |
| Janik, I | 1 |
| Bünemann, H | 1 |
| Heilmann, HP | 1 |
| Nuzzo, A | 1 |
| Lalli, A | 1 |
| De Filippis, S | 1 |
| Torchio, P | 1 |
| Ferrière, JP | 1 |
| Charrier, S | 1 |
| Courtadon, M | 1 |
| Bélembaogo, E | 1 |
| de Latour, M | 1 |
| Achard, JL | 1 |
| Dauplat, J | 1 |
| Chollet, P | 2 |
| Seino, K | 1 |
| Sugoh, T | 1 |
| Mikami, K | 1 |
| Mikami, Y | 1 |
| Hakamada, K | 1 |
| Endoh, M | 1 |
| Konn, M | 1 |
| Cakmakli, S | 1 |
| Ersöz, S | 1 |
| Tuğ, T | 1 |
| Karaayvaz, M | 1 |
| Akgül, H | 1 |
| Joaquim, AI | 1 |
| Sagarra, AJ | 1 |
| Ramos, CD | 1 |
| Coudry, R | 1 |
| Sagarra, RA | 1 |
| Camargo, EE | 1 |
| Kinney, AY | 1 |
| Sahin, A | 1 |
| Vernon, SW | 1 |
| Frankowski, RF | 1 |
| Annegers, JF | 1 |
| Frye, DK | 1 |
| Dhingra, K | 1 |
| Emanuel, EJ | 1 |
| Patterson, WB | 1 |
| Yokota, T | 1 |
| Roppongi, T | 1 |
| Kanno, K | 1 |
| Ogata, T | 1 |
| Kurihara, T | 1 |
| Higashi, Y | 1 |
| Suemasu, K | 1 |
| Tabei, T | 1 |
| Ishiguro, S | 1 |
| Iino, Y | 2 |
| Morishita, Y | 2 |
| Takeda, F | 1 |
| Fowble, B | 1 |
| Hanlon, AL | 1 |
| Patchefsky, A | 1 |
| Freedman, G | 1 |
| Hoffman, JP | 1 |
| Sigurdson, ER | 1 |
| Goldstein, LJ | 1 |
| Fujitake, S | 1 |
| Maeda, Y | 1 |
| Shimizu, M | 1 |
| Nozaki, H | 1 |
| Tohyama, M | 1 |
| Kataoka, S | 1 |
| Koizumi, M | 1 |
| Matsumoto, S | 1 |
| Takahashi, S | 1 |
| Yamashita, T | 1 |
| Ogata, E | 1 |
| Nash, MS | 1 |
| Nash, LH | 1 |
| Garcia, RG | 1 |
| Neimark, P | 1 |
| Darut-Jouve, A | 1 |
| Jolimoy, G | 1 |
| Belichard, C | 1 |
| Arnoud, L | 1 |
| Guerrin, J | 1 |
| Jagannathan, NR | 1 |
| Singh, M | 1 |
| Govindaraju, V | 1 |
| Raghunathan, P | 1 |
| Coshic, O | 1 |
| Julka, PK | 1 |
| Rath, GK | 1 |
| Li, G | 1 |
| Liu, F | 1 |
| Chen, Z | 1 |
| Han, S | 1 |
| Park, K | 1 |
| Kim, HY | 1 |
| Lee, MS | 1 |
| Kim, HJ | 1 |
| Kim, YD | 1 |
| Koshizuka, K | 1 |
| Hada, M | 1 |
| Muto, S | 1 |
| Hagiwara, J | 1 |
| Nakagomi, H | 1 |
| Takano, K | 1 |
| Kamiya, K | 1 |
| Tada, Y | 1 |
| Hall, TC | 1 |
| Shokeir, MO | 1 |
| Taylor, MA | 1 |
| Wreggit, GR | 1 |
| Crabo, L | 1 |
| Han, Q | 1 |
| Shen, Z | 1 |
| Yu, L | 1 |
| Arthur, DW | 1 |
| Schmidt-Ullrich, RK | 1 |
| Friedman, RB | 1 |
| Wazer, DE | 1 |
| Kachnic, LA | 1 |
| Amir, C | 1 |
| Bear, HD | 1 |
| Hackney, MH | 1 |
| Smith, TJ | 1 |
| Lawrence, W | 1 |
| Bini, A | 1 |
| Zompatori, M | 1 |
| Ansaloni, L | 1 |
| Grazia, M | 1 |
| Stella, F | 1 |
| Bazzocchi, R | 1 |
| Homma, H | 1 |
| Doi, T | 1 |
| Mezawa, S | 1 |
| Takada, K | 1 |
| Kukitsu, T | 1 |
| Oku, T | 1 |
| Akiyama, T | 1 |
| Kusakabe, T | 1 |
| Miyanishi, K | 1 |
| Niitsu, Y | 1 |
| Feng, J | 1 |
| Zheng, X | 1 |
| Dai, A | 1 |
| Hata, Y | 1 |
| Sasaki, F | 1 |
| Ogita, M | 1 |
| Uchino, J | 1 |
| Yoshimoto, M | 1 |
| Akasaka, Y | 1 |
| Nakanishi, Y | 1 |
| Sawada, Y | 1 |
| Mouret, E | 1 |
| Dorval, T | 1 |
| Palangié, T | 1 |
| Jouve, M | 1 |
| Scholl, S | 1 |
| Extra, JM | 1 |
| Asselain, B | 1 |
| Pouillart, P | 1 |
| Gasparini, G | 1 |
| Biganzoli, E | 1 |
| Bonoldi, E | 1 |
| Fanelli, M | 1 |
| Boracchi, P | 1 |
| Takei, H | 1 |
| Horiguchi, J | 1 |
| Maemura, M | 1 |
| Koibuchi, Y | 1 |
| Yokoe, T | 1 |
| Jordan, VC | 1 |
| Choi, SM | 1 |
| Lee, SH | 1 |
| Yang, YS | 1 |
| Kim, BC | 1 |
| Kim, MK | 1 |
| Cho, KH | 1 |
| Petera, J | 1 |
| Filip, S | 1 |
| Slampa, P | 1 |
| Soumarová, R | 1 |
| Coupek, P | 1 |
| Zatloukal, P | 1 |
| Fujikawa, A | 1 |
| Tsuchiya, K | 1 |
| Katase, S | 1 |
| Kurosaki, Y | 1 |
| Hachiya, J | 1 |
| Mackey, JR | 1 |
| Jennings, LL | 1 |
| Clarke, ML | 1 |
| Santos, CL | 1 |
| Dabbagh, L | 1 |
| Vsianska, M | 1 |
| Koski, SL | 1 |
| Coupland, RW | 1 |
| Baldwin, SA | 1 |
| Young, JD | 1 |
| Cass, CE | 1 |
| Barbareschi, M | 1 |
| Mori, I | 1 |
| Mauri, F | 1 |
| Muscarà, M | 1 |
| Nakamura, M | 1 |
| Yoshimura, G | 1 |
| Sakurai, T | 1 |
| Caffo, O | 1 |
| Galligioni, E | 1 |
| Dalla Palma, P | 1 |
| Kakudo, K | 1 |
| Manziuk, LV | 1 |
| Komov, DV | 1 |
| Khaĭlenko, VA | 1 |
| Artamonova, EV | 1 |
| Mikhina, ZP | 1 |
| Ermilova, VD | 1 |
| Abashin, SIu | 1 |
| Toyama, T | 1 |
| Yamashita, H | 1 |
| Hara, Y | 1 |
| Hikosaka, Y | 1 |
| Kobayashi, S | 1 |
| Iwase, H | 1 |
| Moyses, B | 1 |
| Haegele, P | 1 |
| Lehmann, S | 1 |
| Schraub, S | 1 |
| Zelek, L | 1 |
| Cottu, P | 1 |
| Tubiana-Hulin, M | 1 |
| Vannetzel, JM | 1 |
| Misset, JL | 1 |
| Chouaki, N | 1 |
| Marty, M | 1 |
| Gamelin, E | 1 |
| Culine, S | 1 |
| Mackenzie, S | 1 |
| Langer, F | 1 |
| Eifrig, B | 1 |
| Hegewisch-Becker, S | 1 |
| Marx, G | 1 |
| Neuber, K | 1 |
| Hossfeld, DK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Associations Between Genetic Polymorphisms of Drug Transporter Genes and Toxicity of Doxorubicin and Cyclophosphamide Chemotherapy in Breast Cancer Patients[NCT04654195] | 100 participants (Anticipated) | Observational | 2020-12-01 | Recruiting | |||
| A Randomized Phase III Study Exploring the Efficacy of Capecitabine Given Concomitantly or in Sequence to EC-Doc With or Without Trastuzumab as Neoadjuvant Treatment of Primary Breast Cancer[NCT00288002] | Phase 3 | 1,500 participants (Anticipated) | Interventional | 2005-01-31 | Completed | ||
| A Randomized Phase III Study Comparing Epirubicin, Docetaxel and Capecitabine + G-CSF to Epirubicin and Docetaxel + G-CSF as Neoadjuvant Treatment for Early HER-2 Negative Breast Cancer and Comparing Epirubicin, Docetaxel and Capecitabine + G-CSF ± Trastu[NCT00309556] | Phase 3 | 536 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Adjuvant Chemotherapy in Elderly Patients With Breast Cancer: Weekly Docetaxel vs. CMF[NCT00331097] | Phase 3 | 300 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| A Prospective Multicenter Open-label, Randomized Phase II Study of Pembrolizumab in Combination With Neoadjuvant EC-Paclitaxel Regimen in HER2-negative Inflammatory Breast Cancer.[NCT03515798] | Phase 2 | 81 participants (Anticipated) | Interventional | 2018-07-24 | Recruiting | ||
| Phase III Trial Assessing the Interest of a Maintenance Chemotherapy Combining Docetaxel (Taxotere) 5-FU After Induction Treatment by Aintensive Chemotherapy for Inflammatory Breast Cancers[NCT02324088] | Phase 3 | 174 participants (Actual) | Interventional | 2000-10-31 | Completed | ||
| Phase II Study of Trastuzumab (Herceptin) and Capecitabine (Xeloda) in Women With Taxanes and Anthracyclines Refractory Metastatic Breast Cancer and HER2 Over-Expression[NCT00107393] | Phase 2 | 75 participants (Anticipated) | Interventional | 2003-06-30 | Completed | ||
| Efficacy and Safety of Supplement Adjuvant Capecitabine in Postoperative Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative High-risk Breast Cancer Patients: a Multicenter, Single-arm Clinical Trial[NCT05212454] | Phase 3 | 400 participants (Anticipated) | Interventional | 2023-03-15 | Recruiting | ||
| The Impact of a Moderate CAlorie and Protein REstriction PROgram (CARE-PRO) as an Efficient and Affordable Therapeutic Strategy in Patients With Barrett's Esophagus.[NCT03813381] | 160 participants (Actual) | Interventional | 2015-11-30 | Completed | |||
| Evaluation of Dyspeptic Symptoms in Oncological Frail Patients With Extraintestinal Cancer in Chemotherapy. Assessment of Circulating Levels of Glucagon-like Peptide 2 (GLP-2) in Relation to Mucositis[NCT01382667] | 70 participants (Actual) | Observational | 2011-07-31 | Completed | |||
| A Phase II, Randomised Controlled Trial to Evaluate the Efficacy and Safety of Moisturising Creams With or Without Palm-oil-derived Vitamin E Concentrate in Addition to Urea-based Cream or Urea-based Cream Alone in Capecitabine-associated Palmar-Plantar E[NCT05939726] | 90 participants (Anticipated) | Interventional | 2023-05-16 | Recruiting | |||
| Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine: A Randomized Controlled Trial.[NCT05641246] | Phase 2 | 66 participants (Anticipated) | Interventional | 2022-12-08 | Active, not recruiting | ||
| A Multi-center Randomized Phase III Study Evaluating 4 Cycles of Docetaxel, Doxorubicin and Cyclophosphamide Versus 4 Cycles of Vinorelbine and Capecitabine in Patients Not Sufficiently Responding to 2 Cycles of TAC and 4 Cycles of TAC Versus 6 Cycles of [NCT00544765] | Phase 3 | 2,014 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| An Open-label Randomized Clinical Trial to Compare the Toxicities and Efficacy of Pharmacokinetically-guided and BSA Fixed Dosing Strategy of Docetaxel and Paclitaxel in Chinese Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, and Breast Cancer Patie[NCT01891123] | 300 participants (Anticipated) | Interventional | 2013-06-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for fluorouracil and Carcinoma, Ductal, Breast
| Article | Year |
|---|---|
Interaction between capecitabine and brivudin in a patient with breast cancer.
Topics: Aged; Anemia, Aplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 2010 |
Antineoplastic agent-associated serpentine supravenous hyperpigmentation: superficial venous system hyperpigmentation following intravenous chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2010 |
Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, | 2011 |
[Liver arterial infusion chemotherapy with adjuvant trastuzumab for the simultaneous treatment of liver and breast cancer-a case report].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Ne | 2012 |
Ten-year outcome after combined modality therapy for inflammatory breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carci | 2003 |
Invasive ductal carcinoma within a fibroadenoma of the breast.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Breast Neoplasms; Carcin | 2004 |
[Clinical research advancement on male breast cancer].
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis | 2007 |
Case report: Second primary small cell carcinoma of the trachea in a breast cancer survivor: a case report and literature review.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Duct | 2008 |
Arterial thrombosis associated with granulocyte-macrophage colony-stimulating factor (GM-CSF) administration in breast cancer patients treated with dose-intensive chemotherapy: a report of two cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcino | 1995 |
Bilateral recurrent pneumothorax complicating chemotherapy for pulmonary metastatic breast ductal carcinoma: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cycloph | 2000 |
45 trials available for fluorouracil and Carcinoma, Ductal, Breast
| Article | Year |
|---|---|
Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Prote | 2020 |
A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2020 |
German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcino | 2013 |
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2014 |
Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitab | 2014 |
Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; C | 2015 |
Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Chemotherapy, | 2015 |
Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast N | 2015 |
UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Axilla; Carc | 2015 |
UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Axilla; Carc | 2015 |
UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Axilla; Carc | 2015 |
UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Axilla; Carc | 2015 |
Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brea | 2017 |
Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2009 |
Variations in gene expression and response to neoadjuvant chemotherapy in breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Duct | 2009 |
Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitab | 2010 |
Prolonged disease control after myeloablative chemotherapy, autologous transplantation and immunotherapy in high-risk early breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; | 2010 |
Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers | 2010 |
Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecita | 2011 |
[Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capec | 2011 |
Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)].
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2011 |
TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasm | 2011 |
Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2012 |
Oxidative stress parameters in women with breast cancer undergoing neoadjuvant chemotherapy and treated with nutraceutical doses of oral glutamine.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protoc | 2011 |
Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2012 |
Preventing weight gain during adjuvant chemotherapy for breast cancer: a dietary intervention study.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, | 2012 |
The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemoth | 2013 |
Pathologic changes related to CMF primary chemotherapy in breast cancer. Pathological evaluation of response predicts clinical outcome.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2002 |
Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcino | 2003 |
Adjuvant chemotherapy for elderly patients (> or =70 years) with early high-risk breast cancer: a retrospective analysis of 260 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; C | 2005 |
Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemoth | 2005 |
Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2006 |
Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Ca | 2006 |
Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2007 |
[Efficacy of docetaxel combined capecitabine on metastatic breast cancer].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 2007 |
Clinical study on treatment of mammary cancer by shenqi fuzheng injection in cooperation with chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Car | 2007 |
[Comparison of tolerance and toxicity of CEF-100 regimen versus CEF-60 regimen as adjuvant therapy for breast cancer].
Topics: Adult; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransfer | 2007 |
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Al | 2008 |
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biom | 2008 |
[Clinical study of ambulatory cancer chemotherapy for recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 1994 |
[Comparison of the therapeutic effect of CMxMF and CAMF regimens in the management of advanced breast cancer patients].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brea | 1993 |
Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Carcinoma in Situ; Carcino | 1996 |
Activity of standard-dose carboplatin, cyclophosphamide, and etoposide in patients with metastatic breast cancer with previous exposure to anthracyclines.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1997 |
The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Neoplasm; Antigens, Tumor-Associated, Carbohydrate; | 1997 |
[Influence of preoperative on gastric cancer tissues and cells].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 1997 |
A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Ductal, Breast; Cathet | 2000 |
Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridg | 2002 |
190 other studies available for fluorouracil and Carcinoma, Ductal, Breast
| Article | Year |
|---|---|
Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA2 Protein; Carcinoma, Ductal, Breast; Carcinoma, | 2019 |
Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2017 |
TYMS Gene Polymorphisms in Breast Cancer Patients Receiving 5-Fluorouracil-Based Chemotherapy.
Topics: Adult; Antimetabolites, Antineoplastic; Breast; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, B | 2018 |
Association of immunohistochemically defined molecular subtypes with clinical response to presurgical chemotherapy in patients with advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinom | 2013 |
Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inh | 2013 |
The role of oncoplastic breast surgery in the management of breast cancer treated with primary chemotherapy.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, | 2013 |
Gut peptide profile and chemotherapy-associated dyspepsia syndrome in patients with breast cancer undergoing FEC60 chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemoth | 2013 |
Early-onset brain metastases in a breast cancer patient after pathological complete response to neoadjuvant chemotherapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2013 |
[Potential indications for helical tomotherapy in breast cancers].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2014 |
Failure and success in the treatment of breast carcinoma in men: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Back Pain; Breast Neoplasms, Male; Carcinoma, Ductal | 2014 |
Expression of nuclear factor kappa B (NF-κB) as a predictor of poor pathologic response to chemotherapy in patients with locally advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Duct | 2014 |
Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer.
Topics: Adult; Age Factors; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Asia; Breast Neoplas | 2014 |
Lack of prognostic value of mean corpuscular volume with capecitabine therapy in metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Car | 2014 |
Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Axilla; Bi | 2014 |
Correlation of tumor-infiltrative lymphocyte subtypes alteration with neoangiogenesis before and after neoadjuvant chemotherapy treatment in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Duct | 2014 |
The actual scenario of neoadjuvant chemotherapy of breast cancer in developing country: a report of 80 cases of breast cancer from a tertiary cancer center in India.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2014 |
Outcomes of immediate perforator flap reconstruction after skin-sparing mastectomy following neoadjuvant chemotherapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2015 |
Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compound | 2015 |
BRCA2-associated therapy-related acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Duct | 2015 |
Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Brea | 2015 |
Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Prediction of pathological complete response to neoadjuvant chemotherapy by magnetic resonance imaging in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2015 |
Saddle pulmonary embolus and bronchiolitis obliterans with organizing pneumonia develop simultaneously after first cyclophosphamide, methotrexate, 5FU chemotherapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; | 2015 |
Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Agents; Azacitidine; Carcinoma, Ductal, Breast; Carcinoma, | 2016 |
Rates of major complications during neoadjuvant and adjuvant chemotherapy for early breast cancer: An off study population.
Topics: Acute Coronary Syndrome; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 2016 |
Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2016 |
Combination of shear wave elastography and Ki-67 index as a novel predictive modality for the pathological response to neoadjuvant chemotherapy in patients with invasive breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; | 2016 |
Coincidential successful treatment of Jessner-Kanof disease with chemotherapy.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylati | 2008 |
Capecitabine-induced coronary vasospasm.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; C | 2008 |
Bilateral inflammatory metachronic ERBB2 (HER2/neu)-positive breast carcinoma: prolonged survival with combined chemotherapy and trastuzumab.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplas | 2008 |
Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Br | 2009 |
A case of capecitabine-induced hyperpigmentation and radiation recall phenomenon.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; D | 2009 |
[Choroidal metastasis from a breast carcinoma. Diagnosis and follow-up with optical coherence tomography and fluorescein angiography and autofluorescence with HRA-II (Heidelberg Retina Angiograph)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; C | 2009 |
Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cisplat | 2009 |
Expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in human breast carcinoma cells and tissues.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Cell Line, Tumor; | 2009 |
[Efficacy of neoadjuvant chemotherapy with FEC and TEC regimen on breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2009 |
Severe drug-induced thrombocytopenia after treatment with trastuzumab but not with lapatinib.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; | 2009 |
Growth fraction as a predictor of response to chemotherapy in node-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2010 |
Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcino | 2009 |
[A case of giant breast cancer performed a radical excision after neoadjuvant chemotherapy].
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylatin | 2009 |
Rho GDP dissociation inhibitor alpha expression correlates with the outcome of CMF treatment in invasive ductal breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinom | 2010 |
[A case of premenopausal stage IV breast cancer responding to neoadjuvant endocrine therapy after chemotherapy with FEC].
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2010 |
Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy.
Topics: Aldehyde Dehydrogenase; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylase | 2010 |
[Long-term response of liver metastases of breast cancer to capecitabine--case report].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycyt | 2010 |
Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
A case of metastatic breast cancer successfully treated with lapatinib plus capecitabine therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Capecitabine; Carcinoma, D | 2011 |
Neoadjuvant chemotherapy for locally advanced premenopausal breast cancer in Nigerian women: early experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; | 2010 |
The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up.
Topics: Adult; Amenorrhea; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2010 |
GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Brazil; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosph | 2010 |
Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2011 |
Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumo | 2010 |
[Two cases of HER2-positive advanced or metastatic breast cancer, responding to lapatinib and capecitabine].
Topics: Adenocarcinoma, Scirrhous; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplas | 2010 |
Specific congenital malformations after exposure to cyclophosphamide, epirubicin and 5-fluorouracil during the first trimester of pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ductal, Breast; Cyclophosphamide; | 2011 |
[A case of HER2 overexpressing advanced breast cancer with CTF therapy [cyclophosphamide, pirarubicin (THPADM), fluorouracil] showed long-term effectiveness after paclitaxel shock].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineopl | 2010 |
[A case of multicentric breast cancer in which an effect of neoadjuvant chemotherapy had a disparity].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcino | 2010 |
Sternal metastasis of breast cancer: ex vivo hypothermia and reimplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Breast Neoplasms; Ca | 2011 |
Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachial Plexus Neuropathies; Carcinoma | 2012 |
Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; | 2012 |
Cisplatin as an active treatment in zoledronate-refractory hypercalcemia.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma | 2011 |
Case of epirubicin-induced cardiomyopathy in familial cardiomyopathy.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Cardiac | 2011 |
Off-label use of oxaliplatin in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast | 2011 |
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brea | 2012 |
Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast | 2011 |
Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2011 |
Ubc9 expression predicts chemoresistance in breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; | 2011 |
[Primary systemic therapy in breast cancer patients (2007-2010)].
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; | 2011 |
A prognostic model to predict outcome of patients failing to achieve pathological complete response after anthracycline-containing neoadjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brea | 2012 |
[Predictive value of (99)Tc(m)-MIBI scintimammography in evaluation of the efficacy of neoadjuvant chemotherapy in patients with operable breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2011 |
[A case of breast cancer liver metastases responding to lapatinib and capecitabine therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, B | 2011 |
The role of chemoradiotherapy in patients with unresectable T4 breast tumors.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Proto | 2013 |
Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinom | 2012 |
The fibroblast growth factor receptor 1 (FGFR1), a marker of response to chemoradiotherapy in breast cancer?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinom | 2012 |
Mandibular metastases as first clinical sign of an occult male breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Carcinoma, Ductal, Bre | 2012 |
Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy.
Topics: Acid Phosphatase; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone and | 2012 |
[Efficacy analysis of THP-containing regimens as neoadjuvant and adjuvant chemotherapy for primary breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2012 |
[A case of cutaneous mammary re-irradiation].
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Ch | 2012 |
Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biom | 2013 |
Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Proteins; Brea | 2013 |
Ulcerated plaques in the pelvic region of an adult female.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Carcinoma, D | 2012 |
Study of chromosome damage in patients with breast cancer treated by two antineoplastic treatments.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; | 2002 |
Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Breast Ne | 2002 |
Therapy-related myelodysplastic syndrome after autologous stem cell transplantation for breast cancer.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, D | 2002 |
[Breast carcinoma in accessory gland: a case report].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neop | 2002 |
Therapy-induced leukemias and myelodysplastic syndromes after breast cancer treatment: an underemphasized clinical problem.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Carci | 2002 |
High incidence of central nervous system involvement in patients with breast cancer treated with epirubicin and docetaxel.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; | 2002 |
Increased dihydropyrimidine dehydrogenase activity in breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma | 2003 |
Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Ca | 2003 |
Simultaneous occurrence of hepatic focal nodular hyperplasia and uterine endometrial stromal nodule in a patient having treated breast infiltrating ductal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; | 2003 |
Response of neoplastic meningitis from solid tumors to oral capecitabine.
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcin | 2003 |
Using loco-regional recurrence as an indicator of the quality of breast cancer treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; C | 2004 |
[Two cases of breast cancer markedly responded to neoadjuvant chemoendocrine therapy (2 cycles of CMF and tamoxifen, pCR and near pCR)].
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2004 |
Muehrcke's lines on nails after cyclophosphamide/adriamycin/fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cycloph | 2004 |
Estrogen receptor-associated expression of keratinocyte growth factor and its possible role in the inhibition of apoptosis in human breast cancer.
Topics: Adenocarcinoma; Apoptosis; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Lin | 2004 |
Pseudoneoplastic proliferation of histiocytes with paclitaxel-induced ultrastructural changes in a mastectomy specimen.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2004 |
[Effects of neoadjuvant chemotherapy on estrogen and progesterone receptors and HER-2 in breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2004 |
[A case of advanced breast cancer markedly responding to chemo-endocrine therapy with only slight alopecia].
Topics: Adenocarcinoma, Scirrhous; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm | 2005 |
Thymidylate synthase predicts for clinical outcome in invasive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2005 |
Potential role of chemo-radiation with oral capecitabine in a breast cancer patient with central nervous system relapse.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2006 |
Chemotherapy for breast cancer during pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; | 2005 |
Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2005 |
Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecita | 2006 |
Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecita | 2006 |
Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecita | 2006 |
Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecita | 2006 |
Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Du | 2006 |
Detection of infraclavicular lymph node metastases using ultrasonography in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Du | 2005 |
[Clinical analysis of 67 patients with brain metastases from breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carc | 2005 |
[A paclitaxel-resistant case of recurrent breast cancer responded to combination therapy of capecitabine and trastuzumab].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; An | 2005 |
Choroidal metastasis from breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, B | 2006 |
Actinic keratosis and capecitabine therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; De | 2005 |
Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2006 |
Coronary artery spasm induced by capecitabine.
Topics: Adult; Angina Pectoris; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, | 2006 |
S-1 (TS-1) maintained complete response for approximately 10 years in a case of metastatic breast cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplas | 2006 |
Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycyt | 2006 |
Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy.
Topics: Alternative Splicing; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; C | 2006 |
[Case report of advanced breast cancer responding to capecitabine and trastuzumab combination therapy].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2006 |
Success of neoadjuvant chemotherapy in conversion of mastectomy to breast conservation surgery.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Ant | 2006 |
A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapy.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2006 |
[Breast carcinoma and bone chondrosarcoma: a new syndrome?].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Breas | 2006 |
Multiple cutaneous metastases from male breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; C | 2006 |
Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 2006 |
Infiltrating ductal carcinoma and synchronous malignant phyllodes tumour. Diagnostic and therapeutic approaches.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemoth | 2006 |
[A patient with advanced breast cancer refractory to chemotherapy accompanied by carcinomatous pleurisy and multiple bone metastasis that responded to combination therapy with high-dose toremifene and docetaxel].
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplas | 2007 |
[A case of inflammatory breast cancer achieving pathological complete response by primary systemic therapy with CEF (cyclophosphamide, epirubicin, 5-fluorouracil) followed by docetaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combine | 2007 |
t(8;16) AML developed subsequent to breast cancer therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone M | 2006 |
Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy, Fine-Needle; Breast Neo | 2007 |
[Assessment of neoadjuvant chemotherapy in breast cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2006 |
Male breast cancer with mandibular metastasis. A case report.
Topics: Aged; Androstadienes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplast | 2007 |
Parotid gland metastasis of a breast cancer.
Topics: Anastrozole; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Al | 2007 |
The effect of chemotherapy on Ki-67, Bcl-2 and Bak expression in primary tumors and lymph node metastases of breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; bcl-2 Homologous Ant | 2007 |
Diabetes insipidus revealing an isolated pituitary stalk metastasis of breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; | 2007 |
Complete remission of recurrent breast cancer with multiple liver metastases after oral capecitabine and injected trastuzumab.
Topics: Administration, Oral; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2007 |
[Diagnosis and prognosis study of breast carcinoma with micropapillary component].
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone N | 2007 |
Concomitant intensive chemoradiotherapy induction in non-metastatic inflammatory breast cancer: long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2007 |
[A case of elderly metastatic breast cancer with a complete response to treatment with capecitabine and cyclophosphamide].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Ch | 2007 |
Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Densi | 2007 |
DNA damage in peripheral blood lymphocytes in patients during combined chemotherapy for breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2008 |
Integrated gene expression profile predicts prognosis of breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, | 2009 |
Determining the morphological features of breast cancer and predicting the effects of neoadjuvant chemotherapy via diagnostic breast imaging.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carci | 2008 |
Treatment of breast cancer with trastuzumab during pregnancy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2008 |
Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplas | 2009 |
Vinblastine and 5-fluorouracil sensitivity of xenografts of four pancreatic ductal adenocarcinomas: is there a correlation with histological and cytological tumour differentiation?
Topics: Animals; Antineoplastic Agents; Carcinoma, Ductal, Breast; Cell Differentiation; Female; Fluorouraci | 1995 |
Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tum | 1994 |
Changes in Tc-99m radionuclide bone scan images and peripheralization of marrow hematopoietic activity associated with the administration of granulocyte colony stimulating factor as an adjunct to dose-intensified chemotherapy for breast cancer. A case rep
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Breast Neoplasms; Carcinoma, | 1994 |
[Persistent granulocytosis and hyperuricemia after a single G-CSF injection (Filgrastim) in treatment of chemotherapy-induced myelosuppression in metastatic breast carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Carcinoma in Si | 1995 |
Breast cancer: are imaging studies cost effective following breast cancer and adjuvant therapy?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; | 1995 |
[A case of inflammatory breast cancer treated with preoperative intra-arterial infusion chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; | 1994 |
Histologic grade of locally advanced infiltrating ductal carcinoma after treatment with induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy, Needle; Breast Neoplasm | 1994 |
Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcino | 1994 |
Dose-intensive therapy for breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Bra | 1993 |
A case of advanced male breast cancer successfully treated by 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy combined with tamoxifen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms, Male; Carcin | 1995 |
Neoadjuvant chemotherapy in locally advanced breast cancer.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breas | 1996 |
Adjuvant hormonal treatment with peptide YY or its analog decreases human pancreatic carcinoma growth.
Topics: Carcinoma, Ductal, Breast; ErbB Receptors; Fluorouracil; Gastrointestinal Hormones; Humans; Leucovor | 1996 |
Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, | 1996 |
Bone marrow changes induced by recombinant granulocyte colony-stimulating factor resembling metastatic carcinoma: distinction with cytochemical and immunohistochemical studies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Bone Marrow; B | 1996 |
Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy.
Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic A | 1995 |
Treatment of advanced breast cancer: How much chemotherapy is enough?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; | 1996 |
[A case of non-resectable pancreatic cancer surviving more than 4 years by intra-arterial infusion chemotherapy with angiotensin-II].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ductal, Breast; Combined | 1996 |
In vitro chemosensitivity of human pancreatic cancer cell lines.
Topics: Aged; Antimetabolites; Antineoplastic Agents; Carcinoma, Ductal, Breast; Cisplatin; DNA Replication; | 1996 |
P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 1997 |
[Combined breast-preserving surgery, chemotherapy and radiotherapy in the treatment of breast carcinoma. Effect of the interval between surgery and the beginning of radiotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 1997 |
Adjuvant chemotherapy with doxorubicin-containing regimen for 326 stage II breast cancers: 15-year results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 1997 |
[A case of unresectable pancreatic cancer successfully treated with continuous venous daily infusion of 5-FU and low-dose CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ductal, Breast; Cisplatin; Drug Administr | 1997 |
Intra-arterial infusion chemotherapy in the treatment of locally advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antine | 1997 |
Tc-99m sestamibi scintimammography in the evaluation of response of breast carcinoma to chemotherapy.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylati | 1997 |
Ethics of randomized clinical trials.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; | 1998 |
[A case report of advanced breast cancer with remarkable response to chemoendocrine therapy (CTF + MPA)].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bre | 1998 |
Multidrug-resistant recurrent breast cancer which responded to medroxyprogesterone acetate showing a remarkable improvement in the quality of life: report of a case and the role of team medical care.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas | 1998 |
The presence of proliferative breast disease with atypia does not significantly influence outcome in early-stage invasive breast cancer treated with conservative surgery and radiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neopl | 1998 |
[A case of giant advanced breast cancer responding remarkably to chemo-endocrine therapy chiefly with doxifluridine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, D | 1998 |
Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer.
Topics: Adult; Alkaline Phosphatase; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 1999 |
Nonselective debridement and antimicrobial cleansing of a venting ductal breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cycloph | 1999 |
[Neoadjuvant chemotherapy FEC-HD in locally advanced breast cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, | 1999 |
Volume localized in vivo proton MR spectroscopy of breast carcinoma: variation of water-fat ratio in patients receiving chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Carcinoma, Ductal, | 1998 |
Reduced expression of p27Kip1 protein is associated with poor clinical outcome of breast cancer patients treated with systemic chemotherapy and is linked to cell proliferation and differentiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 1999 |
[A case of recurrent breast cancer successfully treated with docetaxel].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1999 |
Treatment of mammographically detected minimal breast cancer in an older woman.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; C | 2000 |
[Prognosis and adjuvant chemotherapy of axillary node-negative breast cancer patients].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, | 1997 |
Accelerated superfractionated radiotherapy for inflammatory breast carcinoma: complete response predicts outcome and allows for breast conservation.
Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; | 1999 |
[A clinical report of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 1998 |
Intratumoral pyrimidine nucleoside phosphorylase (PyNPase) activity predicts a selective effect of adjuvant 5'-deoxy-5-fluorouridine (5'DFUR) on breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combin | 2000 |
Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Du | 2000 |
Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2001 |
Tamoxifen-failed male breast cancer with a high level of circulating estrogen: report of a case.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Breast Neoplasms, Male; Car | 2001 |
5-fluorouracil-induced leukoencephalopathy in patients with breast cancer.
Topics: Adenocarcinoma, Mucinous; Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Brain; Breast Neop | 2001 |
Management of inoperable carcinoma of the breast by curative radiotherapy and chemo-hormonotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2001 |
Diffusion-weighted MR imaging of Carmofur-induced leukoencephalopathy.
Topics: Adult; Antineoplastic Agents; Brain; Brain Diseases; Breast Neoplasms; Carcinoma, Ductal, Breast; Ch | 2001 |
Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers.
Topics: Affinity Labels; Animals; Antibodies, Monoclonal; Antibody Formation; Antimetabolites, Antineoplasti | 2002 |
Prognostic value of thymidine phosphorylase expression in breast carcinoma.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2002 |
[Combination therapy of patients with locally advanced breast cancer].
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 2001 |
Successful management of breast cancer with liver metastases with medroxyprogesterone acetate treatment.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2001 |
Assessment of response by breast helical computed tomography to neoadjuvant chemotherapy in large inflammatory breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Al | 2002 |
[Complicated antiphospholid antibody syndrome].
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiphospholipid Syndrome; Breast Neoplasms; Carcino | 2002 |